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ABSTRACT OF THE DISSERTATION
The role of Fibroblast Growth Factor-9 in influenza A virus pathogenesis
by
Bradley Hiller
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2022
Professor Deborah J. Lenschow, Chair
Influenza A virus (IAV) is a respiratory virus in the Orthomyxoviridae family which
causes both seasonal epidemics and pandemics. IAV preferentially infects epithelial cells in the
upper and lower respiratory tract, resulting in a range of disease severity from mild upper
respiratory infections to potentially-lethal pneumonia. Ultimately, the severity of symptoms and
complications from IAV infection depends on control of virus replication in the lungs, the
inflammatory nature of the immune response, and the effectiveness of post-infection lung repair
to regain pulmonary function. An arsenal of secreted proteins in the lung regulates these
antiviral, inflammatory, and regenerative activities during infection, including interferons (IFNs)
and other cytokines, chemokines, and growth factors. Fibroblast growth factors (FGFs) are a
family of signaling proteins that are crucial for tissue development and maintenance and, in
recent years, FGFs in particular have become appreciated for their myriad and pleiotropic roles
in promoting or suppressing viral infection. Fibroblast Growth Factor-9 (FGF9) is required for
lung development, can display antiviral activity in vitro, and is upregulated in asymptomatic
patients during early IAV infection. Therefore, we evaluated FGF9’s ability to regulate
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respiratory virus infection and interrogated IAV pathogenesis in mice that overexpress FGF9 in
club cells in the conducting airway epithelium (FGF9-OE mice).
In my thesis work, we found that FGF9-OE mice were highly susceptible to IAV
infection and displayed persistent IAV titers compared to control mice. As early as 1 day postinfection (dpi), FGF9-OE mice displayed elevated expression of cytokines and chemokines in
the lung and increased numbers of infiltrating innate immune cells. Gene expression analysis in
the airway epithelial cells revealed an elevated type I IFN signature in the airways of FGF9-OE
mice at 1 day post-infection, including a significant upregulation of antiviral IFN-stimulated
genes. However, these changes were driven by viral infection, since FGF9 overexpression alone
resulted in a limited increase in cytokines, chemokines, or ISG expression. In an effort to
determine how this IFN signature in airway epithelial cells impacted IAV tropism, we uncovered
a dramatic shift in infection from the conducting airway epithelium to the alveolar epithelium in
FGF9-OE lungs at 1 dpi, in addition to persistent alveolar infection at 6 dpi in areas of significant
alveolitis. These results demonstrate that FGF9 signaling primes the conducting airway
epithelium to rapidly induce a localized, protective IFN response during viral infection but
simultaneously allows for early and enhanced infection of the alveolar epithelium, ultimately
leading to increased alveolar inflammation and more severe disease. Collectively, our studies
illuminate a novel role for FGF9 in regulating respiratory virus infection and the quality of the
lung’s immune response to infection. Furthermore, the development of this model and utilization
in infection studies will serve as the impetus for future research, including how FGF9 may
regulate IFN signaling in certain cell types, the regulation of inflammatory immune responses
during respiratory virus infection, and FGF9’s potential impact on post-infection lung repair.
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Chapter 1: Introduction
1.1 Influenza viruses
Influenza viruses are respiratory pathogens in the Orthomyxoviridae family which cause
significant morbidity and mortality worldwide. Symptoms from influenza virus infection span a
wide range of disease severity, from relatively mild infections confined to the upper respiratory
tract (characterized by fever, runny nose, cough, muscle pain, and sore throat) to severe infection
of the lower respiratory tract resulting in pneumonia, secondary bacterial infection, pulmonary
hemorrhage, necrosis, and respiratory failure (Denney and Ho, 2018; Krammer et al., 2018;
Short et al., 2016, 2014; Toolsie et al., 2019). Currently, we classify influenza viruses into four
types: influenza A virus (IAV) and influenza B virus cause the majority of human infections
during seasonal epidemics, influenza C virus causes mild disease in humans and is not thought to
contribute to seasonal epidemic disease burden, and influenza D virus is not known to infect
humans (Blümel et al., 2009; Wolff and Veit, 2021). In addition to seasonal epidemics, IAV has
caused four pandemics in the last century in 1918, 1957, 1968, and 2009 with high infection and
mortality rates due to the emergence of IAV strains antigenically distinct from circulating strains
(Taubenberger and Kash, 2010). Since IAV is a major contributor to annual epidemics and the
only known influenza type to cause pandemics (Houser and Subbarao, 2015), IAV will be the
focus of this thesis.

1.2 Influenza A virus
1.2.1 IAV structure
All influenza viruses are enveloped viruses containing a segmented, negative sense,
single-stranded RNA genome. The IAV genome is found within eight viral ribonucleoproteins
1

(vRNPs) consisting of eight RNA segments bound by viral nucleoprotein (NP) (encoded by
RNA segment 5) and three viral RNA-dependent RNA polymerase (RdRp) subunits: PB1
encoded by RNA segment 2, PB2 encoded by RNA segment 1, and PA encoded by RNA
segment 3 (Fig. 1.1A) (Krammer et al., 2018). The scaffolding matrix protein M1 (encoded by
RNA segment 7) internal to the lipid envelope is thought to provide structural integrity to the
virion. Embedded within the lipid envelope are three proteins: membrane protein M2 is encoded
along with M1 in RNA segment 7, sialic acid-binding hemagglutinin (HA) encoded by RNA
segment 4 which mediates viral attachment and entry, and neuraminidase (NA) encoded by RNA
segment 6 which cleaves surface sialic acid to allow for viral egress. RNA segment 8 encodes
nonstructural protein 1 (NS1) and nuclear export protein (NEP).

Figure 1.1 Influenza A virus structure and life cycle.
(A) Diagram of an IAV virion. (B) The IAV replication cycle inside a host cells. Adapted from Krammer
et. al., 2018.

2

1.2.2 IAV life cycle and infection of respiratory cells
IAV primarily targets differentiated epithelial cells of the upper and lower respiratory
tract, including ciliated cells, club cells, and type I and type II alveolar epithelial cells (AT1 and
AT2 cells, respectively) (Heaton et al., 2014; Sanders et al., 2011). At the IAV-host cell
interface, HA on the viral envelope binds to α-2,3-linked or α-2,6-linked sialic acid-decorated
glycoproteins expressed on the host cell surface (Weis et al., 1988), triggering endocytosis into
the host cell (Fig. 1.1B); it is thought that avian HAs preferentially bind α-2,3-linked sialic acids
while human HAs preferentially bind α-2,6-linked sialic acids (Nobusawa et al., 1991; Rogers
and Paulson, 1983). Upon endocytosis, the virus particle is trafficked to the endosome where low
pH activates the M2 ion channel and causes a conformational change in the HA structure,
initiating fusion of viral and endosomal lipid membranes and precipitating release of the eight
vRNPs into the host cytoplasm (Bui et al., 1996; Martin and Heleniust, 1991). The vRNPs are
trafficked to and imported into the host cell nucleus (Martin1 and Helenius2, 1991; O’Neill et al.,
1995), where the viral RdRp transcribes the IAV RNA to ultimately produce complimentary
viral RNA (cRNA) and viral mRNA (Fodor, 2013). Following export of the new viral mRNA
from the nucleus to the cytosol and endoplasmic reticulum, IAV proteins are made using the host
cell translation machinery. NP and viral polymerase subunits are imported back into the nucleus
to make new vRNPs from the viral cRNA, and the vRNPs and then exported back into the
cytosol (Huet et al., 2010; Lee et al., 2017; York and Fodor, 2013). Following localization of
IAV membrane proteins M1, M2, HA, and NA and vRNPs to the host cell plasma membrane
(Dou et al., 2018), new virus particles bud from the plasma membrane and egress with the help
of NA sialidase activity (Burnet et al., 1947; Gottschalk, 1957).
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Figure 1.2 Type I and type III IFN production following pathogen sensing.
Stanifer et. al., 2019. Virus infection and sensing by PRRs induces expression of type I and type III IFNs,
which bind their cognate receptors and result in the activation of ISGs.

1.2.3 The host response to IAV infection in the lungs
IAV infection of respiratory epithelial cells, fibroblasts, and abortive infection of immune
cells leads to virus recognition by multiple pattern recognition receptors (PRRs), including Tolllike receptors (TLRs), nucleotide-binding oligomerization domain-like receptor family pyrin
domain-containing 3 (NLRP3), and most significantly cytoplasmic PRR retinoic acid-inducible
gene-I protein (RIG-I) (and possibly even by nuclear-residing RIG-I) (X. Chen et al., 2018;
Jørgensen et al., 2018; Jung and Lee, 2020; Liu et al., 2018). Canonically, signaling pathway
activation downstream of RIG-I ultimately results in the phosphorylation of interferon (IFN)
regulatory factor 3 (IRF3) and IRF7 and the induction of type I IFNs and type III IFNs, which
activate hundreds of IFN-stimulated genes (ISGs) producing antiviral proteins, cytokines and
chemokines, and more IFNs (Fig. 1.2) (Coccia et al., 2004; Ivashkiv and Donlin, 2013;
4

Manicassamy et al., 2010). During IAV infection of respiratory epithelial cells, type III IFNs
(IFNλ2/3 in mice) primarily induce production of antiviral ISGs in the epithelium as a first line
of defense (Andreakos et al., 2017; Galani et al., 2017). However, if viral infection overcomes
the IFNλ2/3-mediated antiviral defense, type I IFNs (primarily IFNβ and IFNαs) predominantly
expressed by alveolar macrophages result in the production of additional antiviral ISGs as well
as pro-inflammatory cytokines and chemokines to initiate the innate immune response
(Andreakos et al., 2017; Jung and Lee, 2020).
In addition to type I IFN-mediated cytokine and chemokine expression, IAV-infected
cells produce cytokines and chemokines, including IL-6, IL-8, TNF-α, CCL2/MCP-1,
CCL3/MIP-1α, and CCL5/RANTES, which recruit multiple innate immune cells (neutrophils,
NK cells, monocytes, macrophages, and dendritic cells [DCs]) to the site of infection (Jung and
Lee, 2020; Veckman et al., 2006; Wareing et al., 2007, 2004). Efficient neutrophil and NK cell
recruitment and activation is required for reducing viral titers and promoting effective CD8+ T
cell responses during IAV infection; however, overactive neutrophil and NK cell accumulation
or activation can lead to detrimental inflammation and immunopathology (Brandes et al., 2013;
Hwang et al., 2012; Liu et al., 2003; Tate et al., 2008; Tumpey et al., 2005; Zhou et al., 2013).
Type I IFN signaling and CCL2 recruit high numbers of monocytes into the lungs during IAV
infection, where they frequently differentiate into monocyte-derived DCs (moDCs)(Lin et al.,
2008; Seo et al., 2011). The role of moDCs in IAV infection is currently unclear, although they
may help limit viral replication but also contribute to inflammation in the lungs (Cao et al., 2012;
Ramsburg et al., 2011). Both lung resident and recruited DCs are crucial for initiating the
adaptive immune response by initiating antiviral CD8+ T cell responses to clear IAV-infected
cells, although DCs may also contribute to immunopathology and acute lung injury (ALI)
5

(Guilliams et al., 2013; Lin et al., 2008). Lung resident and monocyte-derived alveolar
macrophages are also critical for regulating IAV pathogenesis. In addition to being a primary
source of type I IFNs during IAV infection, alveolar macrophage phagocytic activity and
cytokine and chemokine expression are crucial to defend the alveolar epithelium from rampant
IAV infection, avoid secondary infection by opportunistic respiratory bacteria, suppress
inflammation, and return the lungs to homeostasis (Califano et al., 2018; Cardani et al., 2017a;
Ghoneim et al., 2013; Kim et al., 2008; Somerville et al., 2020).
Growth factors are vital signaling proteins that regulate the development and
maintenance of multiple tissues, including the lungs (Kumar et al., 2005). However, only a few
studies have investigated the roles of growth factors and growth factor receptors during IAV
infection. IAV infection increases transforming growth factor β (TGF-β) expression and IAV NA
directly activates latent TGF-β, which then reduces viral titers and mortality in mice (Carlson et
al., 2010; Schultz-Cherry and Hinshaw, 1996). Insulin-like growth factor 1 (IGF1) is expressed
during IAV infection of A549 cells and BALB/c mice, which then aggravates the IAV-induced
inflammatory response by regulating the expression of inflammatory cytokines (Li et al., 2019).
While it has been shown that epidermal growth factor receptor (EGFR) promotes IAV entry into
host cells, the role of EGFR in promoting or suppressing IAV pathogenesis may vary depending
on lethal or non-lethal infection models (Eierhoff et al., 2010; Mitchell et al., 2019). Finally,
multiple fibroblast growth factors (FGFs) have been shown to influence IAV infection and
pathogenesis by disparate mechanisms (Nikolaidis et al., 2017; Quantius et al., 2016; Wang et
al., 2018), demonstrating that the roles of FGFs during respiratory virus infection merit
continuing exploration.
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1.3 Fibroblast growth factors
The FGF family is comprised of multiple subfamilies of paracrine-signaling canonical
FGFs, endocrine FGFs, and intracellular FGFs (iFGFs) that are expressed in nearly every tissue
(Ornitz and Itoh, 2015, 2022; Tacer et al., 2010). iFGFs have direct functions in the nucleus and
primarily regulate voltage-gated sodium (Nav) channels (Laezza et al., 2007; Liu et al., 2003,
2001; Lou et al., 2005). The canonical and endocrine FGFs are secreted proteins which serve
essential functions during organogenesis as well as in adult tissues, where they regulate tissue
maintenance, metabolism, regeneration, and repair. These secreted FGFs perform these functions
through binding to the extracellular domain of four transmembrane tyrosine kinase FGF
receptors (FGFRs) with varying specificity and differential potencies (Table 1.1).
Alternative splicing of the four mammalian FGFRs results in seven distinct receptors,
FGFRs 1b, 1c, 2b, 2c, 3b, 3c, and 4. Canonical FGFs tightly bind heparan sulfate (HS) as a cofactor for FGFR binding, which keeps canonical FGF signaling local by limiting diffusion
through the extracellular matrix, whereas endocrine FGFs in the FGF15/19 subfamily require
either αKlotho or βKlotho as a cofactor for FGFR binding (Matsuo and Kimura-Yoshida, 2013;
Ornitz, 2000; Potthoff et al., 2012; Smith et al., 2014). Binding of FGFs to FGFRs lead to the
phosphorylation of adaptor proteins activating the PI3K-AKT, RAS-MAPK, PLCγ, and STAT
intracellular signaling pathways which regulate various cellular functions including cell
proliferation, differentiation, survival, immunity, metabolism, or motility (Ornitz and Itoh, 2015,
2022).
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Table 1.1 FGF subfamilies, receptor specificities, cofactors, and signaling

1.4 FGFs and the lung
1.4.1 FGFs and lung development
Multiple FGFs are essential for mediating lung development during organogenesis,
including FGFs 1, 2, 7, 8, 9, 10, and 18 (Danopoulos et al., 2019; Lebeche et al., 1999; Ornitz
and Yin, 2012; Usui et al., 2004; Andrew C White et al., 2006; Yin and Ornitz, 2020a). FGF1
promotes branching by stimulating lung epithelial cells to form buds, while FGF7 promotes
epithelial proliferation and differentiation and promotes expression of surfactant protein A and
surfactant protein B (Cardoso et al., 1997). FGF1 and FGF2 are also involved in regulating the
fate of the lungs in the ventral foregut endoderm (El Agha et al., 2017). Both FGF9 and FGF10
8

are essential for driving the pseudoglandular stage of lung development, where mesotheliumderived FGF9 promotes mesenchymal growth primarily by signaling through FGFR1 and
FGFR2 (White et al., 2006; Yin et al., 2011). Additionally, FGF9 promotes distal epithelial fate
specification and inhibits epithelial differentiation by signaling through FGFR3 and activating
downstream PI3K pathways, whereas FGF10 signals through FGFR2b and activates downstream
MAPK pathways to promote epithelial proliferation and differentiation (Yin and Ornitz, 2020b).
In later stages of fetal lung development, FGF8 and FGF18 are required to form functional
alveoli (Usui et al., 2004; Yu et al., 2010).

1.4.2 FGFs in pulmonary disease
FGF signaling plays extensive roles in multiple respiratory diseases (Fig. 1.3). Pulmonary
arterial hypertension (PAH) is a disease in which pulmonary vascular remodeling leads to
progressively increased pulmonary vascular blood pressure, vascular resistance, and ultimately
heart failure. FGF2 stimulates excessive proliferation of vascular smooth muscle cells and
contributes to PAH, likely by signaling through FGFR1 (Felix et al., 2019; Izikki et al., 2009;
Kim et al., 2012; Schultz et al., 2006). FGF1 signaling on pulmonary arterial smooth muscle
cells was also shown to contribute to hypoxia-induced PAH, while FGF21 could reduce hypoxiainduced apoptosis of endothelial cells and prevent endothelial dysfunction characteristic in PAH
(A. Chen et al., 2018; Li et al., 2003).
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
restriction caused by a chronic inflammatory response of the conducting airways. Patients with
FGF10 haploinsufficiency develop COPD (Klar et al., 2011), and FGF23 is associated with
systemic inflammation in COPD patients (Gulati et al., 2019; Krick et al., 2018). Healthy
remodeling of the bronchial epithelium and smooth muscle surrounding the airways is critical to
9

slow the progression of COPD. One study found FGF1, FGF2, and FGFR1 were significantly
increased in the bronchial epithelium or airway smooth muscle of COPD patients, and may
contribute to lung regeneration and increased pulmonary blood flow (Barnes, 2016; Kranenburg
et al., 2005). Similarly, injection of FGF7 into a COPD mouse model reduced inflammation and
alveolar cell death, protecting the mice from elastase-induced COPD (Plantier et al., 2007).
Asthma is characterized by chronic obstruction of the conducting airways due to
abnormally elevated Th2 cytokines, eosinophilic inflammation, and mast cells. In one study,
FGF21 levels positively correlated with the number of mast cell progenitors and negatively
correlated with lung function (Salomonsson et al., 2019). Recently, FGF2 has been of particular
interest in asthma research due to its ability to regulate inflammatory cells and its role as a
central mediator between immune cells and structural cells in the lung (Tan et al., 2020).
Specifically, elevated FGF2 levels in the lung are associated with smooth muscle hyperplasia and
vascular endothelial cell proliferation (Bossé and Rola-Pleszczynski, 2008; Ogawa et al., 2018).
Multiple studies have implicated FGF signaling in promoting lung repair after lung
injury. FGF2 administration into the lungs was found to protect the lungs from bleomycininduced lung injury and pulmonary fibrosis (Guzy et al., 2015a; Koo et al., 2018). One study
found that FGF7 could enable clearance of alveolar edema fluid in mice, suggesting that FGF7
could promote survival in patients with ARDS; however, a phase 2 trial found that treating
ARDS patients with FGF7 did not significantly improve patient outcomes (McAuley et al.,
2017). FGF10 was found to protect from lipopolysaccharide (LPS)-induced lung injury by
increasing the number of lung-resident mesenchymal stromal cells, as well as drive the
regeneration of basal cells and bronchial epithelial stem cells to repair damaged lung tissue after
10

injury (Tong et al., 2016; Yuan et al., 2019). FGF21 was found to reduce acute lung injury by
regulating NF-κB and reducing inflammation (Gao et al., 2020).
Because FGF signaling effectively regulates cell growth, proliferation, survival, and
angiogenesis, FGFs have been commonly found in association with many solid tumors, including
lung cancer. In patients with non-small cell lung cancer (NSCLC), high FGFR1, FGFR2, and
FGFR3 expression is commonly found in NSCLC tumor samples (Theelen et al., 2016).
Additionally, FGF2-FGFR1 signaling can regulate autophagy in NSCLC cells (Yuan et al.,
2017). High FGF19 expression has been detected in some lung squamous cell carcinoma (LSCC)
patients, and FGF19-FGFR4 signaling was later found to promote LSCC (Li et al., 2020; Zhang
et al., 2017). In adenocarcinoma patients, increased FGF7-FGFR2 signaling is associated with
poor prognosis (Yamayoshi et al., 2004). Finally, several studies demonstrate that FGF9-FGFR3
signaling in the lung epithelium leads to airway epithelial hyperplasia and development of
adenocarcinoma (Yin et al., 2016; Yin et al., 2013), further demonstrating that aberrant FGF
signaling can promote cancerous growth.
Recently, multiple studies have implicated FGF signaling in the pathogenesis of
idiopathic pulmonary fibrosis (IPF), which is a chronic interstitial lung disease which leads to
respiratory failure due to a progressive accumulation of scar tissue. The pathogenesis of IPF is
primarily associated with excessive fibroblast and myofibroblast proliferation and deposition of
extracellular matrix (Kim et al., 2017). FGF9 is elevated in tissue samples from patients with
mild to severe idiopathic pulmonary fibrosis (IPF), although FGF9 and FGF18 were found to
inhibit myofibroblast differentiation in tissue culture (Coffey et al., 2013; Joannes et al., 2016).
FGF1 has also been shown to inhibit myofibroblast differentiation, as well as enhance
11

proliferation of airway epithelial cells (Shimbori et al., 2016). FGF2 is able to act as an
antifibrotic factor in the lung by decreasing fibroblast differentiation and stress fiber formation,
while FGF21 inhibits the excessive deposition of extracellular matrix (Koo et al., 2018; Zhang et
al., 2018). Interestingly, FGF10 regulates mesenchymal cell differentiation and FGF10
deficiency may ultimately be the cause of IPF progression (Wu et al., 2018).

Figure 1.3 The contribution of FGFs and FGFRs to human lung diseases.
Yang et. al. 2021. FGF signaling can promote or alleviate multiple human lung diseases, including
inflammatory diseases such as COPD, PAH, and asthma, IPF, ALI, and multiple cancers.

1.5 FGFs and viral infections
Several recent studies have found that FGFs can regulate virus infection, often by
inhibiting the antiviral response (Table 1.2). For example, FGF7 treatment of keratinocytes
enhanced herpes simplex virus-1, lymphochoriomeningitis virus (LCMV), and Zika virus
(ZIKV) infection by inhibiting ISG expression (Maddaluno et al., 2020a). Additionally, Zika
12

Table 1.2 The roles of FGFs in promoting or suppressing viral infection or disease

virus infection of human fetal astrocytes induced the expression of FGF2, which suppressed IFN
signaling and facilitated Zika virus infection and spread (Limonta et al., 2019). However, a
screen of 756 human secreted proteins identified FGF1, FGF8, and members of the FGF9
subfamily (FGFs 9, 16, and 20) as inhibitors of vesicular stomatitis viruses (VSV) replication in
HAP1 cells in a manner independent of type I interferon (IFN) signaling (van Asten et al., 2018).
The addition of IFNα in combination with FGF16 was able to augment the antiviral effect,
showing that the FGF signaling and IFN signaling were able to independently but cooperatively
suppress VSV replication.
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As primarily secreted proteins, FGF levels in serum may prove to be valuable biomarkers
for multiple diseases. Biomarkers are useful readouts for detecting early human
immunodeficiency virus (HIV) infection, determining HIV incidence in a population, and
evaluating the severity of HIV infection and recurrence. Elevated serum FGF21 may serve as an
important biomarker for poor bone homeostasis and severe hepatic steatosis in HIV-infected
patients (Gallego-Escuredo et al., 2017; Praktiknjo et al., 2019). In HIV patients using
antiretroviral therapy, serum FGF21 levels can be predictors of inflammatory status and
diminished FGF21 may serve as a biomarker for an increased risk of cardiovascular disease and
kidney diseases (Atta et al., 2016; Ruiz-Padilla et al., 2020; Wang et al., 2019).
FGFs in the lung have diverse roles during respiratory virus infection. Increased FGF2
and FGF21 levels in plasma of patients infected with COVID-19 disease, caused by SARS-CoV2 infection, were found to correlate with increased COVID-19 disease severity and mortality
(Petrey et al., 2021). Additionally, increased angiogenesis, possibly driven by elevated FGF2
expression, has been reported in lungs from patients with lethal SARS-CoV-2 infection (Meini et
al., 2020). In the past couple years, several studies have specifically found lung FGFs to play
contradictory roles during IAV infection in mice. During IAV infection in mice, FGF7 increases
the severity of IAV infection by accelerating AT2 cell infection and proliferation (Nikolaidis et
al., 2017). During IAV infection of both humans and mice, FGF2 expression is elevated in the
lungs (Wang et al., 2018). FGF2 administration in mice reduced the severity of IAV disease
while knockout of Fgf2 increased IAV lung injury by impairing neutrophil recruitment and
activation (Wang et al., 2018). miRNA-21-3p modulates FGF2 to facilitate influenza A virus
H5N1 replication by refraining type I IFN response (Shi et al., 2020). However, in contrast to
FGF2, FGF10 protects the lung from severe IAV infection by driving epithelial repair (Quantius
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et al., 2016). During IAV infection of humans, increased FGF9 transcripts specifically in the
serum of asymptomatic patients but not symptomatic patients has been observed at 1 day postinfection (dpi), suggesting that FGF9 may function in the early response to IAV infection (Linel
et al., 2014a). Since multiple FGFs and FGFRs are expressed throughout the respiratory tract,
additional exploration into the roles of FGF signaling during respiratory virus infection may
further inform respiratory virus pathogenesis and provide avenues for clinical treatment.

1.6 Fibroblast Growth Factor-9
FGF9, also known as glial activating factor (GAF), is a canonical FGF in the FGF9
subfamily, which has the unique ability to bind the FGFR3b splice variant (Table 1.1). FGF9
signaling is critical in the growth and development of multiple organs and tissues. Fgf9-/- mice
are embryonic lethal, displaying severely hypoplastic lung development, impaired skeletal
growth, sex reversal, impaired cardiomyocyte growth, impaired growth of small intestine and
cecum, and inner ear defects (J. S. Colvin et al., 2001; Jennifer S. Colvin et al., 2001; Lavine et
al., 2005; David M. Ornitz and Itoh, 2015; Pirvola et al., 2004; Zhang et al., 2006). While FGF9
signaling is required for healthy lung development, expression is reduced to basal levels in the
adult lung, with expression in endothelial cells and smooth muscle cells (Coffey et al., 2013).
Due to its requirement for lung development, antiviral activity against VSV, and upregulation in
human peripheral blood during IAV infection, FGF9 may have an undiscovered role during
respiratory virus infection (J. S. Colvin et al., 2001; Linel et al., 2014a; van Asten et al., 2018).

1.7 Aims and Scope of the Thesis
The myriad mechanisms by which FGFs may regulate viral pathogenesis by altering viral
replication or influencing the immune response to infection are only recently coming to light.
This thesis endeavors to uncover how FGF9 influences the lung environment and affects IAV
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pathogenesis in two related aims. The first aim is to characterize the effects of FGF9 expression
in the lung epithelium and its impact on IAV infection. We found that FGF9 expression in the
conducting airway epithelium protected the airway from IAV infection but amplified infection of
the alveolar epithelium. The second aim probes the impact of FGF9 expression in the respiratory
tract on the immune response to IAV infection. We found that FGF9 expression in the
conducting airway epithelium increased the severity IAV and Sendai virus infection due to a
hyperactive inflammatory response, particularly in the lung parenchyma.
Together, the completion of these aims has furthered our understanding of how FGFs
may regulate viral infection and the immune response to infection, as well as FGF9’s specific
roles in the adult lung. Additionally, these aims leave important questions for future
investigating: How does FGF9 expression protect airway epithelial cells from IAV infection?
Why does FGF9 expression in the airway epithelium promote IAV infection of the alveolar
epithelium? How does FGF9 expression increase the severity of Sendai virus infection? How
might FGF9 contribute to post-infection repair of the lung epithelium? Addressing these
questions promises to further evolve our understanding of the diverse mechanisms by which
FGFs positively or negatively regulate respiratory virus infection and the lung immune response.
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Chapter 2: Fibroblast growth factor-9
expression in airway epithelial cells amplifies
the type I interferon response and alters
influenza A virus pathogenesis
2.1 Abstract
Influenza A virus (IAV) preferentially infects conducting airway and alveolar epithelial
cells in the lung. The outcome of these infections is impacted by the host response, including the
production of various cytokines, chemokines, and growth factors. Fibroblast growth factor-9
(FGF9) is required for lung development, can display antiviral activity in vitro, and is
upregulated in asymptomatic patients during early IAV infection. We therefore hypothesized that
FGF9 would protect the lungs from respiratory virus infection and evaluated IAV pathogenesis
in mice that overexpress FGF9 in club cells in the conducting airway epithelium (FGF9-OE
mice). However, we found that FGF9-OE mice were highly susceptible to IAV and Sendai virus
infection compared to control mice. FGF9-OE mice displayed elevated and persistent viral loads,
increased expression of cytokines and chemokines, and increased numbers of infiltrating immune
cells as early as 1 day post-infection (dpi). Gene expression analysis showed an elevated type I
interferon (IFN) signature in the conducting airway epithelium and analysis of IAV tropism
uncovered a dramatic shift in infection from the conducting airway epithelium to the alveolar
epithelium in FGF9-OE lungs. These results demonstrate that FGF9 signaling primes the
conducting airway epithelium to rapidly induce a localized, protective IFN and proinflammatory
cytokine response during viral infection. Although this response protects the airway epithelial
17

cells from IAV infection, it allows for early and enhanced infection of the alveolar epithelium,
ultimately leading to increased morbidity and mortality. Our study illuminates a novel role for
FGF9 in regulating respiratory virus infection and pathogenesis.

2.2 Introduction
Influenza A virus (IAV) is a respiratory pathogen in the Orthomyxoviridae family that
causes both devastating pandemics and seasonal epidemics, resulting in significant morbidity and
mortality worldwide. Once inhaled, IAV primarily targets differentiated epithelial cells of the
upper and lower respiratory tract, including ciliated cells, club cells, and type I and type II
alveolar epithelial cells (AT1 and AT2 cells, respectively) (Sanders et al., 2011). Infection of
these cells, in addition to abortive infection of immune cells, leads to virus recognition by
multiple pattern recognition receptors (PRRs), resulting in the production of proinflammatory
cytokines and type I interferons (IFNs) which activate hundreds of IFN-stimulated genes (ISGs)
(EM et al., 2004; Ivashkiv and Donlin, 2013; Manicassamy et al., 2010). While antiviral ISGs
reduce viral burden and protect neighboring cells from IAV infection, excessive inflammation
from type I IFN-induced cytokines and chemokines can exacerbate lung disease. Therefore,
proper resolution of IAV infection requires a coordinated respiratory epithelial and immune cell
response to limit viral replication, contain inflammation, and promote repair of the lung
epithelium.
Multiple secreted proteins in the lung, including cytokines and growth factors, can
regulate virus infection, the inflammatory response, and post-infection repair to combat severe
IAV disease. Fibroblast growth factors (FGFs) are a family of secreted proteins that regulate
tissue maintenance, metabolism, regeneration, and repair of adult tissues by binding to the
extracellular domain of four transmembrane tyrosine kinase FGF receptors (FGFRs) (David M
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Ornitz and Itoh, 2015; Ornitz and Itoh, 2022). In the developing lung, FGF1, FGF2, FGF3,
FGF7, FGF9, FGF10, and FGF18 all perform essential regulatory functions mediating
organogenesis (Danopoulos et al., 2019; Lebeche et al., 1999; Ornitz and Yin, 2012; Usui et al.,
2004; Andrew C White et al., 2006; Yin and Ornitz, 2020a). FGF signaling is required for
epithelial and mesenchymal maintenance, and elevated FGF signaling or FGF expression can
have beneficial or detrimental impacts upon lung biology. In the adult lung, increased expression
of FGF2, FGF7, and FGF10 promotes repair after lung injury, and FGF10 also promotes
resolution of acute lung injury and acute respiratory distress syndrome (Fang et al., 2014; Guzy
et al., 2015b; Tong et al., 2016). In contrast, FGF9 is elevated in tissue samples from patients
with mild to severe idiopathic pulmonary fibrosis (IPF), and FGF9 and FGF18 both contribute to
the development of IPF in tissue culture (Coffey et al., 2013; Joannes et al., 2016).
FGFs in the lung have diverse roles during respiratory virus infection. During IAV
infection in mice, FGF7 increases the severity of IAV infection by accelerating AT2 cell
infection and proliferation (Nikolaidis et al., 2017). During IAV infection of both humans and
mice, FGF2 expression is elevated in the lungs (Wang et al., 2018). FGF2 administration in mice
reduced the severity of IAV disease while knockout of Fgf2 increased IAV lung injury by
impairing neutrophil recruitment and activation (Wang et al., 2018). FGF10, however, protects
the lung from severe IAV infection by driving epithelial repair (Quantius et al., 2016). During
IAV infection of humans, increased FGF9 transcripts specifically in the serum of asymptomatic
patients but not symptomatic patients has been observed at 1 dpi, suggesting that FGF9 may
function in the early response to IAV infection (Linel et al., 2014a). In addition, a screen of 756
human secreted proteins identified members of the FGF9 subfamily (FGFs 9, 16, and 20) as
inhibitors of vesicular stomatitis virus (VSV) replication (van Asten et al., 2018). Given these
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findings, we hypothesized that FGF9 may provide protective or antiviral functions during IAV
infection in the adult lung.
To test our hypothesis, Fgf9 was placed under doxycycline-inducible control directed by
the Scgb1a1 promoter, allowing us to temporally regulate FGF9 expression and secretion from
club cells (Tichelaar et al., 2000; Andrew C. White et al., 2006). Since club cells comprise the
majority of the conducting airway epithelium in the mouse lung, we expected that expressing
FGF9 in club cells would protect the entire conducting airway epithelium from IAV infection.
However, FGF9-overexpressing mice displayed excessive lung inflammation and alveolar
edema, increased cytokine and chemokine expression, accelerated infection in the alveolar space,
and displayed increased mortality. Characterization of the conducting airway epithelium revealed
that FGF9 overexpression primed the epithelium for an amplified type I IFN response that
protected it from IAV infection. These findings provide important insights into how FGF
signaling in the lung impacts the pathogenesis of respiratory virus disease.

2.3 Results
Generation and characterization of FGF9-overexpressing transgenic mice
To express Fgf9 from club cells in the conducting airway epithelium with temporal
specificity, TRE-Fgf9-IRES-eGfp transgenic mice (White et al., 2006) were mated to transgenic
mice with a reverse tetracycline transactivator (rtTA) driven under the Scgb1a1 promoter
(Scgb1a1-rtTA). This cross, hereafter referred to as FGF9-overexpressing (FGF9-OE) mice,
results in the induction of the rtTA element primarily in club cells after replacing the standard
mouse diet with doxycycline-containing chow (DOX) (Fig. 2.1A).
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Figure 2.1 FGF9 overexpression from club cells after 3 days of DOX administration does not alter
lung histology.
(A) Schematic of the doxycycline chow (DOX)-inducible double-transgenic mouse breeding resulting in
single-transgenic control mice (Scgb1a1-rtTA or TRE-Fgf9-IRES-eGfp) or double-transgenic FGF9-OE
mice (Scgb1a1-rtTA and TRE-Fgf9-IRES-eGfp). (B) DOX was administered to FGF9-OE mice for 1-3
days and Fgf9 was measured in whole lung RNA by RT-qPCR. Data are represented as fold change of
Fgf9 compared to the uninduced lung (0 days post DOX administration). (C-D) Representative images of
control and FGF9-OE mouse lung sections after 3 days of DOX administration; (C) stained with DAPI
(blue), anti-SCGB1A1 (red), and eGFP (green), scale bars = 50 µm, (D) stained with H&E, scale bars =
500 µm. (E-F) FGF9-OE and control mice were given DOX for 3 days, lungs were harvested, and single
cell suspensions were analyzed for epithelial cells by flow cytometry as described in materials and
methods. Data are represented as mean ± SEM.
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Elevated levels of Fgf9 RNA were detected by real-time quantitative PCR (RT-qPCR)
from whole lungs of FGF9-OE mice upon DOX administration for 24, 48, and 72 hours
compared to uninduced FGF9-OE mice (Fig. 2.1B). To further evaluate the induction of the
TRE-Fgf9-IRES-eGfp cassette, lung sections isolated from FGF9-OE mice and mice containing
only the TRE-Fgf9-IRES-eGfp or Scgb1a1-rtTA transgene (hereafter referred to as littermate
“control” mice) were analyzed after 3 days of DOX administration. Lung sections from DOXtreated control mice or from uninduced FGF9-OE mice displayed no detectable eGFP activity in
the airway epithelium (Fig. 2.1C). In contrast, DOX-treated FGF9-OE mice showed eGFP
fluorescence co-localized within the club cells as denoted by SCGB1A1 staining. Furthermore,
histological analysis of the lung sections revealed no gross differences in the conducting airway
or alveolar epithelium or evidence of cellular infiltrates in the lungs between DOX-treated
FGF9-OE mice, DOX-treated control mice, or FGF9-OE mice without DOX (Fig. 2.1D). To
confirm whether 3 days of FGF9 overexpression altered epithelial cell number in the lungs,
FGF9-OE and control mice were administered DOX for 3 days, and whole, right lung lobes were
harvested and analyzed by flow cytometry (Fig. 2.1E). Consistent with our histological analysis
of lung sections, we detected no differences in the number of total epithelial cells (EpCAM +),
conducting airway epithelial cells (EpCAM+CD24+) or alveolar epithelial cells (EpCAM+CD24−)
between control and FGF9-OE mice (Fig. 2.1F).

FGF9-OE mice are more susceptible to respiratory virus infection than
control mice
Given the ability of FGF9 to inhibit recombinant VSVs (van Asten et al., 2018), we
hypothesized that FGF9 may inhibit IAV infection and thereby protect the lungs from severe
disease. To test this hypothesis, FGF9-OE and littermate control mice were continuously
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administered DOX beginning 3 days prior to infection (d-3), infected intranasally (i.n.) (d0) with
IAV A/WSN/33 (WSN), and then monitored for weight loss and survival. Although we expected
the FGF9-OE mice to be protected from IAV infection, all FGF9-OE mice lost weight and
succumbed to infection between 5-9 dpi (Fig. 2.2A-B). In contrast, while the control mice
initially lost weight at the same rate as the FGF9-OE mice, 100% of the control mice recovered
and survived WSN infection.

Figure 2.2 FGF9-OE mice are more susceptible to respiratory virus infection.
(A-B) FGF9-OE and control mice were administered DOX beginning 3 days prior to infection (d-3),
inoculated intranasally (i.n.) on d0 with 6x104 PFU WSN, and monitored for (A) weight loss (control
n=12, FGF9-OE n=8) and (B) survival (control n=31, FGF9-OE n=28). (C-D) DOX-induced FGF9-OE
and control mice were inoculated i.n. on d0 with 5 PFU PR8 (control n=10, FGF9-OE n=8) (C) or 1x104
PFU SeV-52 (control n=23, FGF9-OE n=7) (D) and were monitored for survival. (E) WT FVB/NJ mice
were treated i.n. with PBS (n=7) or 5 µg rFGF9 (n=7) on d-3 and again concurrently with WSN infection
on d0 and were monitored for survival. (F) Survival curve of WSN-infected FGF9-OE mice treated with
DOX 1 day pre-infection (d-1, n=9) or 1 dpi (d+1, n=9) compared to historic d-3 DOX administration
from panel B. For all experiments, weight loss and survival were monitored until 14 dpi. Data were
pooled from 2 or more separate experiments. Data are represented as mean ± SEM and were analyzed by
Mantel-Cox test (*, p < 0.05; **, p < 0.01; ****, p < 0.0001).
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To determine whether FGF9-OE mice were similarly more susceptible to other
respiratory viruses, we evaluated survival of DOX-treated mice infected with IAV A/PR/8/34
(PR8) or Sendai virus (SeV-52). While the majority of control mice recovered from PR8
infection (Fig. 2.2C) and SeV-52 infection (Fig. 2.2D), the FGF9-OE mice were more
susceptible to both respiratory viruses compared to control mice. Together, these results
demonstrate that overexpression of FGF9 from club cells leads to increased susceptibility to
respiratory virus infection. To characterize this FGF9-driven increase in disease, we focused on
elucidating the mechanisms of heightened WSN pathogenesis in FGF9-OE mice since the
difference in survival between FGF9-OE and control mice was most striking during WSN
infection.
Because club cells in the wild-type adult mouse lung do not specifically express high
levels of FGF9, we wanted to dispel the possibility that the FGF9-OE mice are more susceptible
to WSN infection due to unintended effects of the double-transgenic mouse model unrelated to
FGF9 expression. Therefore, we next determined whether recombinant FGF9 (rFGF9) similarly
promoted susceptibility to WSN infection. WT FVB/NJ mice were treated with 5 µg rFGF9 or
PBS i.n. on d-3 and again concurrently with WSN infection on d0, and survival was monitored.
While all PBS-treated mice recovered from WSN infection, nearly all rFGF9-treated mice
succumbed to the infection (Fig. 2.2E), confirming that increased FGF9 in the respiratory tract
enhanced influenza severity. Next, to determine when FGF9 overexpression was required for
increased susceptibility to IAV infection, we induced FGF9 overexpression at varying time
points. FGF9-OE mice were given DOX 1 day prior to infection (d-1) or 1 day post infection
(d+1), were infected with WSN at d0, and were monitored for survival. FGF9-OE mice given
DOX on d-1 displayed intermediate lethality compared to what we observed when treatment was
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initiated on day -3, with approximately 45% of the mice recovering from infection (Fig. 2.2F).
However, if DOX administration was started on d+1, then nearly all the mice survived WSN
infection. Taken altogether, these results demonstrate that forced overexpression of FGF9 in club
cells increases susceptibility to different respiratory viruses, but only if overexpression is
initiated prior to infection.

FGF9-OE mice have delayed viral clearance and exacerbated inflammation
during IAV infection
Increased susceptibility to WSN required FGF9 overexpression prior to infection.
However, lethality in FGF9-OE mice did not occur until 5-6 dpi, likely due to increased viral
burden, altered viral clearance, or an excessive inflammatory response. First, to evaluate the
impact of FGF9 overexpression on viral burden, the lungs of DOX-treated, WSN-infected FGF9OE and control mice were harvested at 1, 3, and 6 dpi to measure infectious virus by plaque
assay. At 1 dpi, the levels of replicating virus did not differ between the control and FGF9-OE
mice (Fig. 2.3A). By 3 dpi, the FGF9-OE mice sustained viral titers of 105 PFU/ml while the
viral titers in control mice were beginning to decline, with an approximate 1-log reduction in
viral burden. At 6 dpi, nearly all the control mice had cleared replicating virus from their lungs,
while the FGF9-OE mice failed to clear infectious virus and still displayed titers as high as 10 4
PFU/ml.
We next scored histopathology in tissue sections collected from DOX-treated FGF9-OE
and control mice at early (1 dpi) and late (6 dpi) infection time points. At 1 dpi, we observed
thickening of the FGF9-OE airways driven by significantly increased peribronchiolitis and a
higher prevalence of squamous epithelial cell metaplasia (Fig. 2.3B-C), compared to relatively
low levels of peribronchiolitis and a lack of squamous epithelial cell metaplasia in control lung
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Figure 2.3 FGF9-OE mice sustain higher viral titers and have increased lung inflammation.
(A-C) FGF9-OE and control mice were administered DOX beginning on d-3 and infected on d0 with
6x104 PFU WSN i.n. Lungs were harvested at 1, 3, and 6 dpi. At each time point, n=6-13 control or
FGF9-OE mice were analyzed. (A) Infectious virus was quantified by plaque assay; dotted line represents
50 PFU/ml (limit of detection). (B) H&E-stained slides at 1 dpi (control n=3, FGF9-OE n=5) and 6 dpi
(control n=1, FGF9-OE n=3) were scored for peribronchiolitis, squamous epithelial metaplasia, airway
epithelial denudation, and alveolitis as described in the Materials and Methods. (C) Representative images
of H&E-stained control and FGF9-OE whole lung sections at 1 and 6 dpi; (bottom) corresponding
magnified insets (scale bars = 200 µm). Data are represented as mean ± SEM and were analyzed within
each time point by unpaired student’s t test (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001).
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sections. By 6 dpi, control mouse lung sections displayed increased peribronchiolitis and
alveolitis characterized by a moderate number of infiltrating leukocytes in the alveolar space. In
contrast, we observed significantly more severe alveolitis in FGF9-OE lung sections at 6 dpi,
characterized by a high number of infiltrating leukocytes, alveolar edema, and alveolar
consolidation. We additionally observed significant denuding of the FGF9-OE airway epithelium
at 6 dpi with severe peribronchiolitis around the remaining conducting airways (Fig. 2.3B-C).
Altogether, these results demonstrate that club cell-driven FGF9 overexpression led to elevated
and sustained viral titers in the lung tissue. We also observed pervasive inflammation of the
airway epithelium and, most significantly, the lung parenchyma during IAV infection,
correlating to when the FGF9-OE mice began to succumb to infection.

FGF9-OE mice display an accelerated and elevated inflammatory response to
IAV
Respiratory epithelial cells are the primary target of IAV replication and are important for
the initial amplification of cytokine and chemokine expression (Oslund and Baumgarth, 2011).
Multiple experimental studies have shown that excessive cytokine and chemokine expression
during IAV infection correlates with increased tissue damage and severity of disease (Guo and
Thomas, 2017; Liu et al., 2016; Tisoncik et al., 2012). Given the increased alveolar inflammation
we observed in FGF9-OE mouse lungs (Fig. 2.3B-C), we next evaluated if these mice displayed
elevated cytokine and chemokine expression throughout infection. FGF9-OE and control mice
were administered DOX beginning at d-3, infected with WSN at day 0, and the right lung lobes
were taken from mice after 3 days of DOX but without infection (0 dpi) or at 1, 3, or 5 dpi (Fig.
2.4A). Cytokine and chemokine protein levels were then quantified in lung homogenates by
multiplex array analysis. In mice given DOX only (0 dpi), several analytes were statistically
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Figure 2.4 Cytokine and chemokine expression is elevated in FGF9-OE lungs during IAV infection.
(A-C) FGF9-OE and control mice were administered DOX beginning on d-3 and infected on d0 with
6x104 PFU WSN i.n. (A) Lungs were harvested prior to infection on d0 (0 dpi) and at 1, 3, and 5 dpi (red
arrows) and whole lung homogenates were analyzed by multiplex cytokine and chemokine analysis. (B)
Data represented in a table as mean fold change of FGF9-OE samples over control samples for each
analyte at 0, 1, 3, and 5 dpi. Data statistics were analyzed within each time point using unpaired student’s
t test (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). No symbol indicates no significant
difference in analyte expression between FGF9-OE and control samples; ND, not determined. (C) Fold
change of 16 selected analytes significantly increased in FGF9-OE samples at 1 dpi compared to control
samples, represented as mean ± SEM at 0 and 1 dpi. Data were analyzed across time points by two-way
ANOVA (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). Dotted lines represent limit of
detection. At each time point, n=5-7 control or FGF9-OE mice were analyzed.
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increased in FGF9-OE lungs compared to control lungs, including IL-7, IL-9, CCL2, CCL4,
CXCL9, and CXCL10, although none of these analytes were increased above 2-fold (Fig. 2.4B).
Strikingly, 16 cytokines and chemokines were significantly elevated in lungs isolated from the
FGF9-OE mice at 1 dpi compared to control mice, including G-CSF, TNFα, IFNγ, IL-6, CCL2,
CCL4, and CXCL9 (Fig. 2.4B-C). Multiple cytokines and chemokines remained highly
expressed at 3 and 5 dpi in the FGF9-OE lysates, including G-CSF, TNFα, IL-6, and CCL2 (Fig.
2.4B).
The initial surfeit of cytokines and chemokines we observed in the FGF9-OE lung lysates
at 1 dpi suggests that FGF9 had driven an increased inflammatory response to infection
considering that there were no significant differences in viral titers at 1 dpi between FGF9-OE
and control mice (Fig. 2.3A). Additionally, sustained cytokine and chemokine expression
through 5 dpi likely results in increased recruitment of immune cells to sites of infection, which
could explain the observed pervasive alveolitis by H&E staining at 6 dpi (Fig. 2.3B-C).
Therefore, we wanted to further characterize the immune environment of the FGF9-OE and
control lungs throughout infection by analyzing conventional immune cell populations. Singlecell suspensions from whole, right lungs of DOX-induced FGF9-OE and control mice were
generated after 3 days of DOX but without infection (0 dpi), at 1 dpi, and at 5 dpi, and the total
number of innate immune cells were quantified by flow cytometry (Fig. 2.5A). Since it was
possible that T cells could be recruited into lung tissue by 5 dpi, we additionally enumerated total
CD4+ T cells, CD8+ T cells, and B cells (Fig. 2.5B). While there were no significant differences
in the total number of CD45+ cells or any immune cell subtypes measured at 0 dpi or 5 dpi,
FGF9-OE lungs displayed a 2-fold increase in the total number of CD45+ cells at 1 dpi (Fig.
2.6A). FGF9-OE lungs had slightly elevated (< 2-fold) numbers of alveolar macrophages (Fig.
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Figure 2.5 Gating strategies for isolating respiratory epithelial cells and innate immune cells by
flow cytometry
(A-B) Representative flow cytometry plots depicting the gating strategy for innate immune cell
subpopulations (A) and lymphocyte subpopulations (B) isolated from control mice lungs

2.6B) and eosinophils (Fig. 2.6C) at 1 dpi compared to control lungs, as well as a 7-fold increase
in neutrophils (Fig. 2.6D), a 2-fold increase in the number of CD103+ DCs (Fig. 2.6E) and
CD11b+ DCs (Fig. 2.6F), a 3-fold increase in the number of Ly6C+ monocytes (Fig. 2.6G) and
CD11b+ macrophages (Fig. 2.6H), and a trend toward elevated moDC numbers at 1 dpi (Fig.
2.6I). At 5 dpi, FGF9-OE lungs had significantly higher Ly6C+ monocytes (Fig. 2.6G) and a
small decrease in the number of CD4+ T cells (Fig. 2.6J) compared to control lungs. Taken
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together, these data indicate that, while 3 days of FGF9 overexpression results in minor increases
in select cytokines and chemokines, the additional stimulus of infection is required to elicit
hyperactive expression of cytokines and chemokines and increased immune cells as early as 1
dpi in FGF9-OE lungs compared to control lungs.

Figure 2.6 Increased numbers of innate immune cells infiltrate into FGF9-OE lungs at 1 dpi.
(A-J) FGF9-OE and control mice were administered DOX beginning on d-3 and infected on d0 with
6x104 PFU WSN i.n. Lung single cell suspensions were generated prior to infection (0 dpi) and at 1 and 5
dpi, and the total number of live cells was determined for the indicated immune cell subpopulation as
described in materials and methods. Data are represented as mean ± SEM and analyzed within each time
point by unpaired student’s t test (*, p < 0.05; **, p < 0.01; ***, p < 0.001). At each time point, n=7-8
control or FGF9-OE mice were analyzed.
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FGF9-OE airway epithelial cells have a strong IFN signature at 1 dpi
Secreted FGFs tightly associate with heparan sulfate proteoglycans on the surface of
cells, which limits their diffusion and allows for robust autocrine and paracrine signaling on
nearby neighboring cells (Ornitz, 2000; Rapraeger et al., 1991; Xu and Esko, 2014; Yayon et al.,
1991). In our FGF9-OE mouse model, FGF9 is secreted from club cells, which comprise the
majority of the conducting airway epithelium in the mouse lung (Danopoulos et al., 2019).
Therefore, we reason that the club cells, ciliated cells, and other epithelial cell types of the
conducting airway are the cells that receive the most FGF9 stimulus and becoming
transcriptionally altered.
To investigate this further, we sorted airway epithelial cells (CD45−CD326+CD24+) (Fig.
2.1E) from 1 dpi lung digests of DOX-induced FGF9-OE and control mice and performed RNAseq on extracted RNA. Gene set enrichment analysis (GSEA) of the Gene Ontology Biological
Processes database revealed that the top 10 most significant positively-enriched pathways in the
FGF9-OE airway epithelial cells compared to control airway epithelial cells at 1 dpi were all
related to the innate immune response and IFN signaling, including “Cellular response to IFNβ,”
“Defense response to virus,” and “Inflammatory response” (Fig. 2.7A, Table 2.1, Fig. 2.8).
Ifnb1, multiple Ifna subtypes (e.g. Ifna11 and Ifna14), and Ifnl2 were all upregulated by 1-3 log
fold change in the FGF9-OE airway epithelial cells at 1 dpi, as well as multiple cytokines and
chemokines (e.g. Il6, Il33, Ccl9, and Cxcl11), and known antiviral ISGs (e.g. Isg15, Oas3, and
Rsad2) (Fig. 2.7B). Importantly, FGF9 was highly upregulated in the FGF9-OE airway epithelial
cells, but was lowly-expressed in the control airway epithelial cells. RT-qPCR analysis of RNA
extracted from sorted airway epithelial cells at 1 dpi validated the upregulation of several of
these genes, including Ifnb1, Isg15, and Rsad2 (viperin) in FGF9-OE airway epithelial cells as
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compared to cells isolated from control mice (Fig. 2.7C). We also assessed ISG15 protein
expression by immunofluorescence microscopy. At 1 dpi we saw a modest upregulation of
ISG15 protein expression in the control airway epithelium, but in the FGF9-OE lungs, ISG15
expression was dramatically upregulated in the airway epithelial cells (Fig. 2.7D). Finally, to
determine if FGF9 signaling alone resulted in this increased IFN signature in the conducting
airway epithelium, we analyzed expression of several genes in FGF9-OE mice that were treated
with DOX for 3 days but were not infected (0 dpi).

RT-qPCR analysis of sorted airway

epithelial cells from FGF9-OE and control mice at 0 dpi revealed no significant differences in
Ifnb1, Isg15, and Rsad2 expression (Fig. 2.7C). We also observed no ISG15 protein expression
by immunofluorescence microscopy in the lungs of FGF9-OE mice following treatment with
DOX but without viral infection (Fig. 2.7D). Together, these data demonstrate that 3 days of
FGF9 overexpression alone does not significantly alter IFN signaling in the conducting airway
epithelium. Instead, high FGF9 signaling sensitizes the airway epithelial cells to induce a rapid,
dramatic IFN signature, especially type I IFN, in conducting airway epithelial cells.
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Figure 2.7 RNA sequencing revealed an elevated IFN response in FGF9-OE airway epithelial cells
at 1 dpi.
(A-D) FGF9-OE and control mice were given DOX beginning on d-3 and infected on d0 with 6x104 PFU
WSN i.n. (A-C) RNA extracted from sorted airway epithelial cells (CD45−CD326+CD24+) at 1 dpi was
analyzed by RNA sequencing. (A) Top 10 most significant positively-enriched pathways, normalized
enrichment scores, and adjusted p-values from GSEA analysis of Gene Ontology Biological Processes
terms comparing control and FGF9-OE airway epithelial cells at 1 dpi. (B) Selected representative genes
and log fold change from GSEA analysis at 1 dpi. (C) RT-qPCR validation of Ifnb1, Isg15, and Rsad2
expression in sorted airway epithelial cells at 0 and 1 dpi. Gene expression was normalized to Gapdh and
graphed as fold change over control (0 dpi) using the 2−ΔΔCt method. Data are represented as mean ± SEM
and analyzed using unpaired student’s t test (**, p < 0.01; ***, p < 0.001). (D) Representative images of
lung sections from control or FGF9-OE mice at 0 and 1 dpi stained with anti-ISG15 polyclonal sera
(yellow) and analyzed by immunofluorescence microscopy (blue = DAPI, scale bars = 100 µm).

34

Table 2.1 List of genes in the most significant positively-enriched pathways in FGF9-OE airway
epithelial cells at 1 dpi.
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Figure 2.8 GSEA plots of the most positively-enriched pathways in FGF9-OE airway epithelial cells
at 1 dpi.
GSEA plots of the top ten most significant (by adjusted p-value) positively-enriched pathways found
upregulated in the FGF9-OE airway epithelial cells as compared to control airway epithelial cells at 1 dpi.

36

FGF9 overexpression results in a shift in IAV tropism from the airway
epithelium to the alveolar epithelium at 1 dpi
Since FGF9-OE airway epithelial cells have increased expression of ISGs as early as 1
dpi, we wanted to investigate how this surplus of antiviral genes might affect the cellular tropism
of WSN. At 1 dpi, we utilized multiplex fluorescent RNA-ISH staining of lung sections to
visualize infected cells. In the control lungs, IAV+ cells were predominantly located in the
conducting airway epithelium, with approximately 45% of airways infected and few IAV+ cells
in the alveolar space (Fig. 2.9A-C). In stark contrast, we identified extremely low levels of
infection in the FGF9-OE conducting airways with approximately 14% of airways infected.
Instead, we observed a dramatic shift in tropism to the alveolar cells at this early time point.
Since FGF9-OE mice maintain high viral titers at 6 dpi (Fig. 2.3A), we investigated whether the
early shift in IAV tropism to the alveoli in FGF9-OE lungs resulted in sustained infection of the
alveoli at 6 dpi. In the control lungs, we detected few IAV+ cells at 6 dpi by multiplex
fluorescent RNA-ISH (Fig. 2.10), consistent with the nearly-undetectable virus titers observed in
control lungs at 6 dpi (Fig. 2.3A). However, there was a dramatic increase in the number of
IAV+ cells in the alveoli of FGF9-OE lungs at 6 dpi, and these areas of alveolar infection were
consistent with areas of alveolitis observed by H&E (Fig. 2.10). Interestingly, we also observed a
scarcity of Scgb1a1 and Sftpc staining in areas of infection in the FGF9-OE lungs at 6 dpi,
consistent with both the alveolitis and airway epithelial denudation observed at 6 dpi by H&E
(Fig. 2.3B-C, Fig. 2.10). Given these observations, we propose that FGF9 expression in the
airway epithelium protects the airway from IAV infection, likely by priming the cells to rapidly
express high levels of IFNs and ISGs upon infection; however, this phenomenon precipitates an
indirect consequence—rapid, robust, and consistent infection of the alveolar cells, resulting in
enhanced alveolar inflammation and exacerbated susceptibility to IAV disease.
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Figure 2.9 IAV tropism is shifted from the airway epithelium to the alveolar epithelium in FGF9OE lungs at 1 dpi.
FGF9-OE and control mice were given DOX on d-3 and infected on d0 with 6x104 PFU WSN i.n. (A-C).
(A) Representative images of multiplex fluorescent RNA-ISH depicting club cells (Scgb1a1, green), AT2
cells (Sftpc, white), and infected cells (Np, red) (blue = DAPI). Images taken with 5X (scale bars = 500

38

µm) and 20X objectives (scale bars = 100µm). (B) The number of infected and uninfected airways was
quantified from multiple FGF9-OE and control lung slides at 1 dpi, with the total percentage of infected
airways per lung section (left) and total number of infected and uninfected cells (right). Infection was
defined as any airway with >1 IAV+ cell. (C) The number of IAV+ cells in the alveolar space was
quantified from blinded 5X images from FGF9-OE and control lung slides at 1 dpi. Data are represented
as mean ± SEM and analyzed using unpaired student’s t test (**, p < 0.01).

Figure 2.10 FGF9-OE lungs have sustained viral infection of the alveoli in areas of alveolitis at 6
dpi.
FGF9-OE and control mice were administered DOX beginning on d-3 and infected on d0 with 6x104 PFU
WSN i.n. Representative images of multiplex fluorescent RNA-ISH depicting club cells (Scgb1a1, green),
AT2 cells (Sftpc, white), and infected cells (Np, red) (blue = DAPI). Images taken with 5X objective
(scale bars = 500 µm).
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2.4 Discussion
FGFs play diverse roles in controlling IAV replication and the immune response to
infection. In the current study, we found that FGF9 overexpression in club cells increased
susceptibility to respiratory infection. It has been well-characterized that increased rapid
infection of alveolar cells by influenza viruses worsens the severity of acute lung injury and
acute respiratory distress syndrome both in humans and animal models (Cardani et al., 2017b;
Herold et al., 2015; Kuiken and Taubenberger, 2008; Nikolaidis et al., 2017; Peteranderl et al.,
2016; Short et al., 2014). We found that the FGF9-OE airway epithelium had a marked reduction
in IAV infection at 1 dpi, but this was accompanied by an increase of infection in the alveoli that
continued through 6 dpi. This accelerated infection of the alveolar space could be driven by
multiple mechanisms. First, the inability to infect the airway epithelium may inadvertently direct
virus into the alveolar space. Alternatively, FGF9 signaling may directly disrupt the barrier
function of the conducting airway epithelium, allowing virus to leak into the alveolar space
during early infection. Finally, it is possible that FGF9 secreted from club cells signals directly to
alveolar epithelial cells and promotes their infection. It is noteworthy that intratracheal
administration of FGF7 (KGF) has been shown to increase both the proliferation of AT2 cells
and their susceptibility to IAV (Nikolaidis et al., 2017). In our FGF9-OE mouse model, FGF9
could be similarly acting on AT2 cells and promoting infection. Future work will assess whether
AT2-driven FGF9 overexpression will similarly increase alveolar cell infection or instead protect
the alveolar epithelium from infection in a similar manner as seen in the FGF9-OE airway
epithelium.
The molecular mechanism underlying how club cell-driven FGF9 overexpression might
promote a type I IFN signature upon infection remains unclear. Within the current literature,
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FGFs commonly inhibit or suppress the functions of IFNs in both disease and development
contexts (Lee et al., 2011; Maddaluno et al., 2020b; Torcia et al., 1999). Recently, multiple
studies have demonstrated that FGF-driven antagonism of IFN signaling can promote viral
pathogenesis. For example, FGF7 treatment of keratinocytes enhanced herpes simplex virus-1,
lymphochoriomeningitis virus, and Zika virus infection by inhibiting ISG expression
(Maddaluno et al., 2020a). Additionally, Zika virus infection of human fetal astrocytes elevated
expression of FGF2, which suppressed IFN signaling and facilitated Zika virus infection and
spread (Limonta et al., 2019). Thus, our observation of an increased IFN signature in FGF9-OE
conducting airway epithelial cells unveils a potentially unique function of FGF9 signaling in the
lung. FGF9 activates FGFR3 in the respiratory epithelium both during organogenesis and
development of lung adenocarcinoma, whereas FGF7 and FGF10 signal through FGFR2b in the
airway epithelium (Yin et al., 2013; Yin et al., 2016; Yin and Ornitz, 2020a). These studies also
reveal that FGF signaling through FGFR3 or FGFR2b activates different signaling pathways,
which could explain how FGF9 primes cells to have an increased IFN response during infection
rather than inhibit IFN signaling and ISG expression. Additionally, FGF9 may instead signal on
nearby fibroblasts or resident immune cells which in turn promote an elevated IFN response in
the airway epithelial cells during infection. FGF9 subfamily member FGF16 was found to be
antiviral against VSV in a secretome screen, and this antiviral effect was independent of IFN
signaling (van Asten et al., 2018). However, the addition of IFN provided further antiviral
activity against VSV in this model, demonstrating that FGF9 subfamily members may have
alternative methods of providing antiviral protection in spite of or in conjunction with IFN
signaling.
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FGF2 can indirectly recruit neutrophils to the lung during IAV infection, thereby
promoting clearance of the virus and protecting the mice from severe disease (Wang et al.,
2018). Our study shows that FGF9 overexpression similarly caused the recruitment of
neutrophils, monocytes, and other innate immune cells to the lungs in conjunction with high
cytokine and chemokine expression as early as 1 dpi. While it is possible that FGF9 has
chemotactic properties in our IAV infection model similar to FGF2, it could be that FGF9
signaling in the lungs partially drives increased cytokine and chemokine expression resulting in
the precocious recruitment of immune infiltrates, which in turn express high levels of cytokines
and chemokines that we detect at 1 dpi. Indeed, our multiplex cytokine analysis revealed a
modest increase in CCL2, CCL4, CXCL9, and CXCL10 in the lungs after 3 days of FGF9
overexpression.
Analysis of IAV tropism in FGF9-OE lungs at 1 dpi revealed a dramatic shift of infection
into the alveolar space that continued through 6 dpi, which supported the severe alveolitis and
alveolar edema we observed in FGF9-OE lungs at later time points. Since respiratory epithelial
cells and alveolar macrophages are often the initial sources of cytokine and chemokine
expression during the early stages of IAV infection, we speculate that the increased infection of
alveolar cells in FGF9-OE lungs provoked a surplus of cytokine and chemokine expression from
both alveolar epithelial cells and alveolar macrophages.
In conclusion, we found that FGF9 overexpression in club cells in the airway epithelium
locally protects the airway from early IAV infection; however, the global consequences were
dire. FGF9-OE mice succumbed to severe disease, characterized by accelerated infection of
alveolar cells and exacerbated inflammation. FGFs function in cellular maintenance and postinjury repair in many tissues and organs. Most treatments for viral infections focus on limiting
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viral replication, but understanding the contributions of FGFs and other growth factors to viral
pathogenesis or protection will likely lead to better therapeutic options that optimally limit
immunopathology during respiratory infection or promote tissue repair after infection.

2.5 Materials and Methods
Ethics Statement
Experiments were approved and performed in accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (National
Research Council, 2011). The protocols were approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine in St. Louis (Assurance number A3381-01).

Establishment of transgenic mice and doxycycline administration
The TRE-Fgf9-IRES-eGfp mice have been previously described (Andrew C White et al.,
2006). Briefly, Fgf9 cDNA was cloned upstream of the IRES-eGfp-SV40 polyA cassette
(pIRES2-eGfp vector, Clontech) in the pTRE2 vector (Clontech)(Santos-Ocampo et al., 1996).
The TRE-Fgf9-IRES-eGfp transgenic mice were mated to Scgb1a1 (Ccsp)-rtTA mice (Tichelaar
et al., 2000). All mouse strains were bred and maintained on the FVB/NJ background in our
mouse colony before being genotyped and transferred to the animal biosafety level 2 laboratory
for infection experiments. Mice were genotyped with PCR primers specific for Scgb1a1-rtTA
(Fwd primer 5’-ACT GCC CAT TGC CCA AAC AC-3’ and Rev primer 5’-AAA ATC TTG
CCA GCT TTC CCC-3’) and TRE-Fgf9 (Fwd primer 5’-GGC GTG TAC GGT GGG AGG CCT
ATA TAA GC-3’ and Rev primer 5’-TAG CTC CCA ACT TCA CCT AAG GGA GCC ATC3’). Doxycycline chow (200mg/kg) (Fisher Scientific) was used to activate the TRE transgene 3
days before viral infection, unless otherwise specified.
43

Virus studies in animals
All influenza A and Sendai virus infection studies were performed in an animal biosafety
level 2 laboratory and followed guidelines established by the Environmental Health and Safety
Committee at Washington University School of Medicine. The principles of Good Laboratory
Animal Care were adhered to in strict accordance with NIH recommendations. Every effort was
made to minimize animal suffering.
Influenza A virus A/WSN/33 (WSN) was provided by Adolfo García-Sastre (Icahn
School of Medicine, Mount Sinai, New York City, NY), and IAV A/PR/8/34 (PR8) was
provided by Jacco Boon (Washington University School of Medicine, St. Louis, MO). Sendai
virus SeV-52 was grown and characterized in the López Lab. At 8-10 weeks of age, mice were
inoculated intranasally in the left nostril with 6x104 PFU of WSN or 5 PFU of PR8 in a volume
of 25 μl PBS or 1x104 PFU SeV-52 in a volume of 40 µl PBS. Experiments included both male
and female mice. For survival studies, weight loss and survival were measured daily for 14 days
and mice were euthanized by carbon dioxide inhalation if they lost more than 30% of their initial
body weight or were significantly moribund. At the termination of all other experiments, mice
were sedated by isoflurane inhalation and euthanized via intracardiac perfusion of PBS.

Tissue viral burden
Organs were harvested in 1 ml PBS and homogenized with 1.0 mm diameter zirconiasilica beads (BioSpec Products) with 1 pulse of 3,000 rpm for 30 sec with a MagNA Lyser
(Roche) prior to plaque assay on MDCK cells. In brief, 200 µl of serial dilutions of organ
homogenates in 1X DMEM (Corning) containing 0.25% BSA and 4 μg/ml N-acetylated trypsin
were added to MDCK cells (5x105 cells for 6 well plates) and incubated for 1 h at 37°C with
rocking every 15 min. Virus was then aspirated and an MEM-agar overlay was added to the cells
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and incubated for approximately 72 h at 37°C. Plates were then fixed with 1% formaldehyde (for
at least 30 min at room temperature) and agar plugs were removed. Plaques were visualized
using a 1% crystal violet solution and counted by hand.

Lung histology and immunofluorescence
Left lungs were inflated, fixed in 10% buffered formalin for 24-48 h, and dehydrated
using 30%, 50%, and 70% ethanol. Lungs were subsequently paraffin-embedded and sectioned
at 5 μm. For histological analysis, sections were deparaffinized with xylene, stained with
hematoxylin and eosin (H&E), and evaluated by light microscopy using a Zeiss Axio Scan.Z1
slide scanner. H&E-stained lung sections were blinded and scored on a scale of 0 to 3 for
peribronchiolitis, squamous epithelial cell metaplasia, alveolitis, and airway epithelial
denudation. Percentage of airways and the area of the lung affected for each type of pathologic
finding was determined. The raw percentage of affected area was multiplied by the intensity
score to acquire the graphed weighted score (Garcia et al., 2020).
For immunofluorescence, 5 μm sections were deparaffinized with xylene, boiled between
98°-102°C for 15 min with Antigen Unmasking Solution (Vector Laboratories), and
permeabilized for 10 min at room temperature with PBS/2% Triton TX-100/1% sodium citrate.
Sections were blocked using PNB buffer (0.5% PNB powder in PBS), antibody and DAPI (4′,6diamidino-2-phenylindole) stained, and visualized by fluorescence microscopy. The following
primary antibodies were used: anti-ISG15 polyclonal rabbit sera (1:250)(Lenschow et al., 2005),
anti-SCGB1A1 goat polyclonal antibody Sc9772 (1:200) (Santa Cruz). Embedding and
sectioning were performed by the Musculoskeletal Histology and Morphometry Core at
Washington University School of Medicine. All samples were visualized using a Zeiss Axio
Imager Z2 fluorescence microscope with ApoTome2 and processed with Zen Pro software.
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Multiplex fluorescence RNA in situ hybridization (RNA-ISH)
Multiplex fluorescence RNA-ISH was performed using RNAscope Multiplex Fluorescent
Reagent Kit v2 (Advanced Cell Diagnostics, Inc., Newark, NJ, USA) according to the
manufacturer’s instructions. Briefly, left lungs were inflated, fixed in 10% buffered formalin, and
paraffin embedded. 5 μm sections were deparaffinized, digested with protease, and hybridized
for 2 h at 40°C with the following RNAscope target RNA-specific probes: V-Influenza-H1N1H5N1-NP (Cat. No. 436221), Mm-Sftpc-C2 (Cat. No. 314101-C2), and Mm-Scgb1a1-C3 (Cat.
No. 420351-C3). Preamplifier, amplifier, HRP-labeled oligos, and TSA plus Cyanine3,
Cyanine5, and fluorescein dyes were then hybridized sequentially at 40°C. The nuclei were
stained with DAPI, and images were acquired as described above. Infection of airways was
quantified by counting the number of infected (>1 IAV+ cell in the airway epithelium) or
uninfected airways in multiple lung sections from 4 FGF9-OE and 4 control mice. Infection of
alveoli was quantified by counting the number of IAV+ cells not associated with the airway
epithelium or endothelium in 3-4 5X images spanning entire lung lobe sections from 4 FGF9-OE
and 3 control mice.

Cytokine and chemokine multiplex analysis
Whole lungs were collected in 1 ml PBS with 0.1% BSA at 0, 1, 3, and 5 dpi and
homogenized with 1.0 mm diameter zirconia-silica beads (BioSpec Products) using a MagNA
Lyser (Roche). Cytokines and chemokines in the homogenates were quantified using Luminex
technology with a MILLIPLEX Map Mouse Cytokine/Chemokine Magnetic Bead Panel 25-plex
Immunology Multiplex Assay (Cat. No. MCYTOMAG-70K-PMX, Millipore) according to the
manufacturer’s instructions, with modifications recommended for “sticky” samples in the
Millipore “tips and tricks” brochure (version 1.0 2017-01180). In brief, these modifications
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included pelleting tissue debris with a 5 min centrifugation step (600 × g) before adding samples
to the 96-well assay plate and running the plate in 1X wash buffer instead of sheath fluid.

Real-time qPCR analysis of host gene expression
Lungs were collected for RNA processing by snap freezing in liquid nitrogen in tubes
with 1.0 mm diameter zirconia-silica beads (BioSpec Products) and transfered to -80°C for
storage. Whole lung RNA was extracted from the tissue using TRIzol Reagent and an RNeasy
Mini Kit (Qiagen). The TRIzol Reagent manufacturer’s protocol was followed up until removal
of the RNA-containing aqueous phase, to which an equal volume of 100% RNase-free ethanol
was added. This solution was added to the RNeasy column, after which the RNeasy Mini Kit
instructions were followed.
For host gene expression, 2 µl of the extracted RNA from WSN-infected or uninfected
mouse lungs were analyzed by quantitative real time PCR (RT-qPCR) using the TaqMan RNAto-Ct 1-Step Kit (Applied Biosystems). Ct values for the gene of interest and the housekeeping
gene Gapdh (glyceraldehyde-3-phosphate dehydrogenase) were used to calculate ΔΔCt, and
normalized. Fold change was calculated by 2-ΔΔCt method (Livak and Schmittgen, 2001). Custom
Taqman primers and probes were acquired from Integrated DNA Technologies to detect Ifnb1:
Ifnb1 FW (5 GTT GAT GGA GAG GGC TGT G 3), Ifnb1 probe (5 /56-FAM/CTG CGT TCC/
ZEN/ TGC TGT GCT TCT C /3IABkFQ/ 3), Ifnb1 RV (5 GGC TTC CAT CAT GAA CAA
CAG 3) (Proenca-Modena et al., 2015). Standard assays from Integrated DNA Technologies
were utilized to detect Gapdh (Mm.PT.39a.1), Isg15 (Mm.PT.58.41476392.g), and Rsad2
(Mm.PT.58.11280480).
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Flow cytometry and analysis
Mice were sacrificed and perfused with PBS as described above. Lung single cell
suspensions were generated by incubation for 1 h at 37°C in 5 ml digestion buffer with manual
shaking every 10-15 min. Digestion buffer for epithelial cell analysis consisted of RPMI
(Sigma), DNase I (10 mg/ml, Sigma), 15 mM HEPES buffer (Corning), and 10% fetal bovine
serum (FBS) (BioWest). Digestion buffer for immune cell analysis additionally included type IV
collagenase (2.5 mg/ml, Sigma). Digested tissues were passed through a 70-µm cell strainer and
washed once with 40 ml PBS containing 5% FBS and treated with red blood cell lysing buffer
(Sigma). The number of viable cells was quantified by trypan blue staining.
The single cell suspension was transferred to a 96-well v-bottom plate, and Fcγ receptors
were blocked with anti-mouse CD16/CD32 (Clone 93; BioLegend) for 15 min at 4°C, followed
by surface staining in PBS containing 5% FBS for 1 h at 4°C. All antibodies were diluted 1:200
and are from BioLegend unless otherwise specified: Fixable Viability Dye eFluor 506 (1:500,
eBioscience); anti-CD45.1 Pacific Blue (A20); anti-I-A/I-E PerCP-Cy5.5 (peridinin chlorophyll
protein-Cyanine5.5) (M5/114.15.2); anti-CD11b Brilliant Violet 605 (M1/70); anti-Siglec F
APC-Cy7 (allophycocyanin-Cyanine7) (E50-2440); anti-Ly6C Alexa Fluor 700 (HK1.4); antiCD11c APC (N418); anti-Ly6G PE-Cy7 (phycoerythrin-Cyanine7) (1A8); anti-CD103 PE
(2E7); anti-CD45 Alex Fluor 700 (30-F11); anti-CD326 PE (G8.8); anti-CD24 APC (M1/69);
anti-CD3ε APC (145-2C11); anti-TCR β chain PE (H57-597); anti-CD4 PE-Cy7 (Gk1.5); antiCD8a Alexa Fluor 700 (53-6.7); anti-CD19 APC-Cy7 (6D5).
After staining, cells were washed and fixed at 4°C for 10 min in 4% paraformaldehyde
(Electron Microscopy Sciences). The fixed cells were washed and resuspended in PBS
containing 5% FBS. Cells were processed on a LSR Fortessa (Becton Dickinson) flow cytometer
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managed by the Flow Cytometry & Fluorescence Activated Cell Sorting Core at Washington
University and analyzed using BD FACSDiva and FlowJo V10 software (Tree Star Inc.).

Bulk RNA sequencing from sorted cells
Whole lung lysates were processed for flow cytometry as described above using
epithelial cell digestion buffer. Whole lungs were combined from 2 mice for each single sample.
Single cell suspensions were incubated with anti-mouse CD16/CD32 (Clone 93; BioLegend) for
15 min at 4°C and then surface stained in PBS containing 5% FBS for 1 h at 4°C. All antibodies
were diluted 1:200 and are from BioLegend: anti-CD45 Alex Fluor 700 (30-F11), anti-CD326
(EpCAM) PE (phycoerythrin) (G8.8), anti-CD24 APC (allophycocyanin) (M1/69).
After staining, cells were washed in PBS containing 5% FBS and CD45− EpCAM+
CD24+ cells were sorted using a Sony Cell Sorter SH800S and Cell Sorter Software V2.1.5
(Sony Biotechnology, Sony Biotechnology). RNA was extracted as described above for RTqPCR analysis. 3 FGF9-OE and 2 control RNA samples were submitted to the Genome
Technology Access Center at the McDonnell Genome Institute at Washington University School
of Medicine for the following analyses. Total RNA integrity was determined using Agilent
Bioanalyzer. Library preparation was performed with 10 ng of total RNA with a Bioanalyzer
RIN score greater than 8.0. ds-cDNA and was prepared using the SMARTer Ultra Low RNA kit
for Illumina Sequencing (Takara-Clontech) per manufacturer's protocol. cDNA was fragmented,
blunt ended, had an A base added to the 3' ends, and then had Illumina sequencing adapters
ligated to the ends. Ligated fragments were then amplified for 12-15 cycles using primers
incorporating unique dual index tags. Fragments were sequenced on an Illumina NovaSeq-6000
using paired end reads extending 150 bases. High quality gene reads were mapped to the Mus
musculus genome and differential gene expression of normalized counts per million was
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analyzed using the Phantasus platform (https://artyomovlab.wustl.edu/phantasus/) developed by
the Sergushichev team at ITMO university. Briefly, gene expression values were Log 2 and
quantile normalized and the top 12,000 most expressed genes were subjected to differential gene
expression analysis using the limma R package. The Gene Ontology Biological Processes
database was used to for pathway enrichment analysis.

Statistical Analysis
All data were analyzed using the Prism software, version 9 (GraphPad), as detailed in the
figure legends using Mantel-Cox test, unpaired, two-tailed student’s t test, or two-way ANOVA
with Tukey’s post-test for multiple comparisons statistical tests. Statistical outliers (p<0.05) were
removed by Grubb’s test for multiplex cytokine/chemokine analysis. All error bars indicate
SEM; if error bars are not visible, then they are shorter than the height of the symbol. Asterisks
indicate statistical significance, with only relevant comparisons shown (*, p < 0.05; **, p < 0.01;
***, p < 0.001; ****, p < 0.0001).

2.6 Closing material
Acknowledgements
This study was supported by grants from the NIH (R01 AI080172 to D.J.L., 5T32
CA009547 to Y.-C.P. and L.E.F., 5T32 AI007163 and F31 AI 14999 to M.C.L., R01 AI134862
and R01 AI137062 to I.A.C. and C.B.L., and R01 HL111190 and R01 HL154747 to D.M.O.)
We also acknowledge support from the Washington University Rheumatic Diseases Research
Resource-based Center (P30 AR073752) for genome engineering and sequencing.
We acknowledge that microscopy imaging was performed in part through the use of the
Washington University Center for Cellular Imaging (WUCCI), which was supported by the
Washington University School of Medicine, The Children’s Discovery Institute of Washington
50

University, St. Louis Children’s Hospital (CDI-CORE-2015-505), Washington University
Rheumatic Diseases Research Resource-based Center (P30 AR073752), and by the Foundation
for Barnes-Jewish Hospital (3770). We acknowledge that all processing of tissues for histology
and H&E staining was performed by the Washington University Musculoskeletal Research
Center, which received funding from the NIH (P30 AR057235). We thank the Genome
Technology Access Center at the McDonnell Genome Institute at Washington University School
of Medicine for help with RNA-seq analysis. The Center is partially supported by NCI Cancer
Center Support Grant #P30 CA91842 awarded to the Siteman Cancer Center and by ICTS/CTSA
Grant# UL1TR002345 from the National Center for Research Resources (NCRR), a component
of the National Institutes of Health (NIH), and by NIH Roadmap for Medical Research. This
publication is solely the responsibility of the authors and does not necessarily represent the
official view of NCRR or NIH.
The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.

51

Chapter 3: Major findings and future
directions
I set out with the goal of examining the potential roles of FGF9 in the lung on IAV
pathogenesis. Here I summarize our findings and the relevant questions going forward.

3.1 Major findings
3.1.1 FGF9 expression in club cells increases the severity of IAV and SeV
infections
Since FGF9 is required for lung development (J. S. Colvin et al., 2001), has some
antiviral activity against VSV in HAP1 cells (van Asten et al., 2018), and is upregulated in the
serum of asymptomatic IAV-infected patients at 1 dpi but not in symptomatic patients (Linel et
al., 2014b), we expected that expression of FGF9 in the lungs would regulate IAV infection and
pathogenesis. In chapter 2 of this thesis, we describe our use of a double-transgenic mouse model
in FVB/NJ mice which allowed us to inducibly-express FGF9 in club cells in the conducting
airway epithelium with spatial and temporal specificity (Fig. 2.1). We find that these FGF9-OE
mice fully succumb to WSN infection compared to littermate control mice (Fig. 2.2). The FGF9OE mice are also significantly more susceptible to PR8 and SeV-52 infections compared to
control mice (Fig. 2.2). WT FVB/NJ mice given rFGF9 intranasally 3 days prior to WSN
infection phenocopy WSN-infected FGF9-OE mice with increased susceptibility to infection.
This FGF9-driven increased severity of WSN infection is dependent on expressing FGF9
multiple days prior to infection (Fig. 2.2). Together, our data indicate that FGF9 expression in
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club cells likely alters the lung environment in a manner that increases the severity of respiratory
virus infection.

3.1.2 FGF9 overexpression enhanced the inflammatory immune response to
IAV infection
Our work describes an increase in peribronchiolitis and alveolitis with a robust increase
in immune cell infiltrates in the alveoli in IAV-infected FGF9-OE lungs compared to control
lungs (Fig. 2.3). When we further analyzed this inflammatory environment with multiplex
cytokine and chemokine analysis, we revealed elevated expression of 16 cytokines and
chemokines in FGF9-OE lungs at 1 dpi that persist throughout infection (Fig. 2.4). Coinciding
with increased cytokine and chemokine expression at 1 dpi is a significant increase in nearly all
innate immune cell populations analyzed in the FGF9-OE lungs (Fig. 2.6). RNA sequencing of
sorted airway epithelial cells from FGF9-OE and control lungs revealed a hyperactive type I IFN
response in the FGF9-OE airway epithelium at 1 dpi (Fig. 2.7), which likely contributed to the
elevated cytokines, chemokines, and immune cells present in the FGF9-OE lungs at 1 dpi.
Furthermore, we did not observe the same elevated type I IFN response after 3 days of FGF9-OE
without infection, demonstrating that increased FGF9 expression alone did not induce this
hyperactive IFN response. Together, these data indicate that FGF9-OE lungs have an
exceedingly inflammatory response to IAV infection as early as 1 dpi. Furthermore, FGF9
overexpression in club cells seems to prime the airway epithelium for a swift, hyperactive type I
IFN response which likely contributes to this profusion of inflammation in IAV-infected FGF9OE lungs.
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3.1.3 FGF9 overexpression alters IAV tropism, promoting more severe
pathogenesis
We observed an inability for FGF9-OE mice to clear infectious virus from the lungs by 6
dpi (Fig. 2.2) and an amplified type I IFN response in FGF9-OE airway epithelial cells at 1 dpi,
including high expression of antiviral ISGs (Fig. 2.7). Therefore, we reasoned that IAV tropism
was likely shifted from the conducting airway epithelium. We analyzed IAV tropism in FGF9OE lungs by multiplex fluorescent RNA-ISH at 1 dpi and found that FGF9-OE airway epithelial
cells were resistant to IAV infection; however, there was an expansion of infected alveolar cells
in FGF9-OE lungs at this early timepoint (Fig. 2.9). We further determined that there was a
persistent and significant population of IAV+ cells in the alveoli of FGF9-OE lungs at 6 dpi
compared to control lungs, and these areas of high alveolar infection corresponded with areas of
high alveolitis seen by H&E (Fig. 2.10). Together, these data demonstrate that IAV infection is
shifted from the conducting airway epithelium in control mice to the alveolar compartment in
FGF9-OE mice, and that the FGF9-OE airway epithelial cells are possibly resistant to IAV
infection due to elevated expression of antiviral ISGs in these cells. Furthermore, the increased
alveolar infection in FGF9-OE lungs likely promotes the severe alveolitis we observe by H&E
(Fig. 2.3) and increased susceptibility to infection (Fig 2.2).

3.2 Future directions
3.2.1 FGF9-driven shift in IAV tropism from the conducting airway to the
alveolar compartment
In Chapter 2, we demonstrate that IAV infection primarily resides in the conducting
airway epithelium with minimal expansion into the alveoli in our DOX-treated control mice.
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However, IAV infection in DOX-treated FGF9-OE mice is primarily in the alveolar
compartment, where it remains and spreads throughout infection. Thus, we have two related
questions regarding this IAV tropism shift in FGF9-OE mice: Why are the airway epithelial cells
resistant to IAV infection? Why is there an increase in alveolar infection?
The FGF9-OE airway epithelium is likely protected from IAV infection due to the
arsenal of antiviral ISGs expressed in these cells as early at 1 dpi; however, we have not yet
provided sufficient evidence to confirm this hypothesis. To determine whether antiviral ISGs are
the cause of diminished airway infection in FGF9-OE mice, future experiments will focus on
blocking type I IFN signaling by two methods. The first method will involve treating mice either
intraperitoneally or intranasally with IFNAR1-blocking antibody prior to and post-infection with
IAV. One obvious drawback using this method of IFNAR1 blockade is that type I IFN signaling
will be blocked globally (by intraperitoneal treatment) or throughout the entire lower respiratory
tract (by intranasal treatment) while we would ideally only target the conducting airway
epithelium. The second method requires us to breed our double-transgenic FGF9-OE and control
mice to mice with genetic deletions in type I IFN signaling specifically on airway epithelial cells,
such as the Foxj1-Scgb1a1-Cre-Stat1f/f mice made by the lab of Michael J Holtzman here at
Washington University (Zhang et al., 2019), or similarly making Foxj1-Scgb1a1-Cre-Ifnar1f/f
mice. These mice are on the C57BL/6J background, so we could additionally consider creating
these mice in the FVBN/J background to match the background of our FGF9-OE and control
mice. Using either method of abrogating type I IFN signaling, we will infect these mice with
IAV and determine viral tropism at 1 dpi by multiplex fluorescent RNA-ISH to determine if
abolishing type I IFN signaling in the airway epithelium diminishes their resistance to IAV
infection.
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Airway epithelial cells may utilize
additional mechanisms to occlude IAV
infection. One possibility is that the FGF9OE airway epithelial cells lack the IAV
entry receptors, which are α-2,3-linked or
α-2,6-linked
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glycoproteins expressed on the host cell
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not performed an extensive analysis of
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Figure 3.1 Lectin staining of sialic acids on the
surface of lung cells.
FGF9-OE and control mice were treated with DOX for
3 days and lungs were harvested on d0. Shown are
representative images displaying lectin staining of
sialic acids in the alveolar space or lining the airway
(“br” = bronchiole). Images taken with 20X objective
(scale bars = 50µm).

immunofluorescence using lectins MAL-II
(specific to α-2,3-linked sialic acid) and SNA (specific to α-2,6-linked sialic acid) suggests that
the FGF9-OE airway epithelium does not have a significant decrease in sialic acid expression
(Fig. 3.1). It is also possible that there is an increase in mucus production in FGF9-OE airway
epithelial cells that blocks virus from the cell surface. While an analysis of muc5ac expression by
immunofluorescence yielded no muc5ac expression in either FGF9-OE or control airway
epithelium at 1 dpi (data not shown), this hypothesis has not been ruled out. A thorough
expression analysis of other mucins may be pertinent in addition to PAS staining of FGF9-OE
and control lung slides to stain mucus-secreting cells. Finally, the FGF9 subfamily members had
antiviral activity against VSV in a secretome screen, and this antiviral effect was independent of
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IFN signaling (van Asten et al., 2018). Thus, it is also possible that FGF9 is inducing a unique
antiviral program in the airway epithelial cells, which can be determined by sorting of the airway
epithelial cells at d0 (3 days DOX only) and performing RNA sequencing.
Increased and persistent alveolar infection in the FGF9-OE lungs could be the result of
several mechanisms. If IAV is unable to enter airway epithelial cells, it is possible that the virus
inoculum simply continues into the alveolar space until it contacts permissive cells. To test this
hypothesis, future experiments could include infecting mice that overexpress FGF9 from alveolar
epithelial cells, such as AT2 cells (Sftpc-Rtta x Tre-Fgf9-Ires-eGfp mice) and testing whether
FGF9 is able to protect the alveolar epithelial cells from infection. Intratracheal administration of
FGF7 (KGF) increased the proliferation of AT2 cells and their susceptibility to IAV (Nikolaidis
et al., 2017). Therefore, it is also possible that FGF9 is similarly acting on AT2 cells and
promoting their infection by IAV. We would then see increased alveolar infection in the previous
suggested mouse model expressing FGF9 from AT2 cells (Sftpc-Rtta x Tre-Fgf9-Ires-eGfp
mice). FGF7-driven infection of AT2 cells was found to be dependent on mTOR signaling,
which was diminished with the inhibitor rapamycin. Treating our FGF9-OE mice with
rapamycin could decrease both alveolar infection and overall IAV pathogenesis if the increased
alveolar infection in our model is similarly governed by mTOR signaling. A future experiment
sorting alveolar epithelial cells in our FGF9-OE mice both with and without IAV infection and
performing RNA sequencing could allow us to determine if there are sets of upregulated or
downregulated genes in alveolar epithelial cells that potentially increase infection, as well as
determine whether FGF9 would prime alveolar epithelial cells for increased type I IFN
expression during IAV infection as it does when expressed in airway epithelial cells. Single cell
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RNA sequencing may additionally allow us to characterize these differences in alveolar cell
populations in an unbiased manner.

3.2.2 FGF9 priming of airway epithelial cells for hyperactive type I IFN
response to IAV
We demonstrated in chapter 2 that 3 days of FGF9 expression in club cells alone does not
induce a robust cytokine or chemokine response nor a type I IFN response; however, there is an
inordinate type I IFN response in sorted airway epithelial cells at just 1 dpi with IAV. These data
suggest that FGF9 expression in or signaling on these airway epithelial cells somehow primes
them to have rapid, elevated type I IFN expression or signaling. RNA sequencing data of sorted
airway epithelial cells from FGF9-OE lungs at 1 dpi show an upregulation of multiple
components of the type I IFN signaling pathway, including PRRs like RIG-I, the initiating IFNs
IFNβ and IFNα4, IFNAR1, multiple STAT proteins, and a myriad of ISGs including other IFNα
subtypes. Sorting airway epithelial cells from FGF9-OE and control lungs without infection (3
days DOX only) and performing RNA sequencing may demonstrate whether any of these type I
IFN pathway components, like RIG-I or IRF3/7, is transcriptionally upregulated from FGF9
overexpression in the absence of infection and initiation of the type I IFN response. Targeted
RT-qPCR of RIG-I, IRF3/7, IFNβ, STAT1, or IRF9 from these sorted airway epithelial cells
may be performed for targeted measurements of their transcription. FGF signaling is known to
induce activation of MAPK pathways, and multiple studies have demonstrated that overactive
MAPK signaling can lead to phosphorylation of STAT1, possibly on S727 as opposed to the
canonical phosphorylation at Y701 downstream of IFNAR1 activation (Ramsauer et al., 2002;
Zhang et al., 2004). Thus, one hypothesis suggests that high levels of FGF9 signaling on airway
epithelial cells in FGF9-OE mice leads to a pool of phosphorylated STAT1 that increases the
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speed and breadth of the IFN response downstream of IFNAR1 activation during IAV infection.
Future experiments may test this hypothesis by flow cytometry or immunofluorescence
microscopy to attempt to measure phosphorylated STAT1 levels specifically in FGF9-OE and
control airway epithelial cells with 3 days of DOX treatment. Additionally, airway epithelial
cells may be sorted to measure total STAT1, p-STAT1 (S727), and p-STAT1 (Y701) levels by
western blot.
An additional tool that will prove useful to tease apart FGF9’s role in priming type I IFN
signaling in airway epithelial cells involves harvesting basal cells from the murine respiratory
tract and differentiating them at air-liquid interface to create murine tracheobronchial epithelial
cells (mTECs). These cells can be harvested from control mice and treated with rFGF9 or
harvested from FGF9-OE and control mice and treated with DOX to study the effects of FGF9
signaling on airway epithelial cells in tissue culture without the need for sorting these cells from
lungs. One caveat to using mTECs is that these cultures primarily differentiate into ciliated cells
with smaller populations of secretory cells, which does not perfectly reflect the murine lung
airway epithelium which is primarily comprised of club cells in addition to ciliated cells and
other rare epithelial cell subtypes. However, protocols may be tested to skew the differentiation
of mTEC cultures to develop more mature secretory cells and better reflect the airway epithelium
of the murine lung.
Another interesting line of questioning which may be the focus of future experiments is
determining the contribution of this FGF9-mediated type I IFN response to overall IAV
pathogenesis in FGF9-OE mice. RNA sequencing of sorted airway epithelial cells at 1 dpi
revealed an elevated expression of several cytokines and chemokines from FGF9-OE cells,
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including IL-6, CCL2, CCL4, CCL5, CXCL9, CXCL10, and CXCL11 (Fig. 2.7). These
chemokines can recruit multiple destructive innate immune cells to areas of lung infection,
including neutrophils, monocytes, and eosinophils, while IL-6 can induce inflammatory
activation of many cell types. The additional upregulation of multiple IFNα subtypes in this data
can further amplify this inflammatory response in the surrounding tissue. Therefore, future
experiments may assess the potential of neutralizing type I IFNs or specific cytokines,
chemokines, or immune cells to determine whether this hyperactive inflammatory response can
be alleviated in IAV-infected FGF9-OE mice.

3.2.3 FGF9-driven type 2 immunity
Interestingly, we observe an increase in Sftpc staining by multiplex fluorescent RNA-ISH
in club cells in the FGF9-OE airway at 1 dpi (Fig. 2.9), suggesting a possible expansion of rare
Scgb1a1/Sftpc (CC10/SPC) dual-positive bronchioalveolar stem cells (BASCs) found in healthy
bronchoalveolar duct junctions. We also observe more Sftpc-expressing club cells in FGF9-OE
lung sections after 3 days of DOX but without infection (d0, 0 dpi) by multiplex fluorescent
RNA-ISH (Fig. 3.2), suggesting that FGF9-OE airway epithelial cells are beginning to
differentiate or dedifferentiate into progenitor-like cells. Interestingly, a COPD model involving
SeV infection also displays increased Sftpc-expressing progenitor-like cells in the airway
epithelium (Byers et al., 2013). In this model, these epithelial progenitor cells in the airway
epithelium express IL-33, which is the coordinating cytokine of type 2 immunity-driven
inflammation and immunopathology.
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Figure 3.2 Sftpc expression in FGF9-OE club cells.
FGF9-OE and control mice were administered DOX beginning on d-3 and lungs were harvested on d0.
Shown are representative images of multiplex fluorescent RNA-ISH showing club cells (Scgb1a1, green),
AT2 cells (Sftpc, white), and ciliated cells (Foxj1, red) (blue = DAPI). Images taken with 20X objective
(scale bars = 50µm).

We performed RT-qPCR on RNA from whole FGF9-OE or control lungs at 0 dpi (3 days
DOX only) and 1 dpi with IAV A/WSN/33 to measure markers of type 2 immunity, including
IL-33, IL-5, IL-13, Retnla/RELMα, Muc5ac, and Arg1 (Fig. 3.3). We additionally measured the
total numbers of ILC2s and γδT cells, two immune cell types commonly associated with type 2
immunity along with eosinophils, in FGF9-OE and control lungs at 1 dpi (Fig. 3.3B). While we
measured some significant increases in IL-13, IL-33, RELMα, and Muc5ac in whole lung RNA
from FGF9-OE at 1 dpi, we did not detect significant differences in ILC2s or γδT cells, nor in
eosinophils (Fig. 2.6), between FGF9-OE and control lungs at 1 dpi. However, we did observe
upregulated IL-33 and Retnla/RELMα in sorted airway epithelial cells from FGF9-OE lungs at 1
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Figure 3.3 Type 2 immunity in FGF9-OE and control lungs.
(A) RT-qPCR analysis of whole lung RNA at 0 and 1 dpi from FGF9-OE and control mice measuring
relative expression (normalized to Gapdh) of Il5, Il13, Il33, Retnla, Muc5ac, and Arg1. (B) Analysis of
total ILC2 and γδT cell numbers in FGF9-OE and control lungs at 1 dpi with WSN by flow cytometry.
(C) Il33, Retnla, and Arg1 expression in RNA sequencing analysis from sorted airway epithelial cells
from FGF9-OE and control lungs at 1 dpi with IAV.

dpi (Fig. 3.3C), indicating that these Sftpc-expressing club cells in the FGF9-OE airway
epithelium could be expressing higher levels of IL-33 as seen in the COPD model in Byers, et.
al., 2013. Together, these data suggest that there may be the induction of at least a partial type 2
immunity signature in the FGF9-OE lungs at 1 dpi compared to control lungs, possibly driven by
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the development of more progenitor-like epithelial cells in the FGF9-OE conducting airway.
While this type 2 immunity signature is only one component of the hyperinflammatory landscape
in the IAV-infected FGF9-OE lungs, the FGF9-OE mouse model may be a valuable tool to
analyze FGF9’s possible role in type 2 immunity in other infectious (SeV, helminths) or noninfectious (asthma, allergy) models dependent on modulating Th2 immune responses. SeV
infection has been shown to drive type 2 immunity in multiple mouse models. Since FGF9-OE
are more susceptible to SeV-52 infection, we are interested in dedicating some future
experiments to illuminating the inflammatory environment of the FGF9-OE lungs during SeV-52
infection to determine if FGF9-driven type 2 immunity has a much more significant contribution
to SeV pathogenesis in the FGF9-OE mice. Additional experiments may also explore the impact
of FGF9 overexpression on the development of SeV-mediated chronic airway disease, such as
the SeV-driven COPD model utilized in Byers et. al., 2013.

3.2.4 Contribution to post-infection lung repair
While IAV infection causes a prolonged period of lung remodeling up to 180 dpi,
morbidity is largely resolved and lung function restored within 3 weeks post-infection (Pociask
et al., 2013). The expansion of Scgb1a1/Sftpc dual-positive cells (putative BASCs) observed in
Fig. 2.9 and Fig. 3.2 represents an interesting possibility in testing whether FGF9 could stimulate
post-infection lung repair. A recent study found that BASCs are able to repopulate both the
airway and alveolar epithelium during recovery from IAV infection (Salwig et al., 2019),
underscoring the possibility that increased highly-regenerative stem cell populations in FGF9-OE
lungs may promote more rapid or largescale repair of the epithelium post infection. We have
demonstrated that increased FGF9 expression prior to IAV and SeV-52 infections increase the
severity of infection (Fig. 2.2), yet delaying the initiation of overexpression of FGF9 until 1 day
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post infection had no impact on survival of acute disease. Therefore, future experiments can
address the effects on FGF9 overexpression in the multi-week lung repair phase after infectious
virus has been cleared. FGF9-OE and control mice will be infected with IAV and only given
DOX for 3-7 days after infectious virus is no longer detectable in the lungs (approximately 9 dpi)
and the mice are beginning to recover lost weight. Since IAV is a lytic virus, causing cell death
in the majority of infected cells, epithelial cells can be quantified by flow cytometry or observed
in situ by immunofluorescence microscopy to compare the numbers of remaining epithelial cells
shortly after infection to the numbers of epithelial cells present in the lung several weeks after
infection. These studies would determine whether short expression of FGF9 in the airway
epithelium after infection increased the numbers of BASC cells present as well as increased the
speed of epithelial cell repopulation post-infection. Other aspects of healthy lung repair can be
measured as well both with and without FGF9 expression once infection is cleared, including
resolution of inflammation, the emergence or krt5+ pods, clearance of immune cells in alveoli,
and epithelial barrier integrity.

3.3 Closing Remarks
The past two years of the COVID-19 pandemic have highlighted both the significance of
and critical necessity for expanded studies investigating how the lung immune response
influences the severity of respiratory virus infection. As respiratory infections become more
prevalent, both in the times of COVID-19 and after, we learn to appreciate that the increased or
decreased expression of even one protein can have dramatic effects on the lung’s development,
plasticity, and ability to combat infection without eliciting immunopathology. As the culmination
of my thesis work, I’ve uncovered multiple phenomena which reveal further questions: (1) FGF9
expression in the murine conducting airway epithelium primes these cells for an overactive IFN
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response, but we have not learned why, (2) FGF9 expression protects the murine airway
epithelium from IAV A/WSN/33 infection, but we have yet to confirm how, (3) FGF9
expression increases infection of the lung parenchyma, though we are unclear why this is, and
(4) FGF9 expression increases the speed and degree of the inflammatory response to IAV
infection, which is likely related to increased alveolar infection and elevated IFN response in the
conducting airways, but has yet to be proven. It has been an interesting time to work in this field,
and I hope my small contributions help guide future work and provoke interest in how small
alterations in the lung environment can have profound consequences for microbial pathogenesis.
Many questions in this unique project remain, which will hopefully unveil new and
exciting lines of questioning in the years to come. Although I’ve listed a few of these questions
in the sections above, two additional questions have eluded us in my time here: (1) the FGFR(s)
that FGF9 is signaling through to regulate IAV infection remains elusive, and (2) how and
whether FGF9 increases pathogenesis of other respiratory viruses remains unknown. I am
hopeful that we’ll continue to see rapid progress in this field, both in terms of understanding
gained and tools developed. From here, I prepare to study new aspects of pneumonia
pathogenesis, and I look forward to reading answers to these and other questions in the future. To
the field, thank you for four years of unique challenges, innovative questions, and interesting
data. To the reader, thank you for your patience and consideration of this dissertation.
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